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Abstract 
Jennifer Leigh Sallee: 
Density-Enhanced Protein Tyrosine Phosphatase 1 (DEP-1) Regulation of Epithelial Cell 
Adhesions 
(Under the direction of Keith Burridge) 
 
Cell-cell adhesions are critical to the development and maintenance of multicellular 
organisms.  Increased tyrosine phosphorylation of junctional proteins has been associated 
with promoting disassembly of protein complexes at junctions and reducing cell-cell 
adhesions.  Levels of tyrosine phosphorylation reflect the balance between protein-tyrosine 
kinase (PTK) and protein-tyrosine phosphatase (PTP) activity.  DEP-1 is a receptor PTP 
which localizes to cell-cell adhesions and has been implicated in regulating phosphorylation 
of junctional proteins.  The catalytically dead substrate-trapping mutant of DEP-1 (DEP-1 
D/A) was used to identify additional substrates at cell-cell junctions.  Members of the tight 
junction, occludin and ZO-1, were found to be substrates of DEP-1.  DEP-1 D/A was not 
only able to bind these proteins in a tyrosine-phosphorylation dependent manner but wild 
type DEP-1 was able to dephosphorylate them.  Occludin and ZO-1 interactions with DEP-1 
were mediated through binding to the catalytic domain of DEP-1 and not by other protein-
protein interaction motifs examined and appear to be specific to DEP-1.  Over-expression of 
DEP-1 increased transepithelial electrical resistance in confluent epithelial monolayers and 
also reduced paracellular flux of FITC-dextran following a calcium switch.  In addition, FAK 
 iv
and paxillin were also identified to be substrates of DEP-1 and indicate that DEP-1 could be 
regulating integrin adhesion-mediated signaling as well.   Future work will focus on mapping 
the occludin residues necessary for DEP-1 interaction and will help to clarify potential 
signaling pathways and kinases upstream of DEP-1 activity.  By controlling phosphotyrosine 
levels of tight junction proteins and perhaps focal adhesion proteins, DEP-1 may play a role 
in regulating permeability and junction formation in epithelial cells.    
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Chapter 1: 
Introduction
 
The regulation of cell-cell adhesion is important in many physiological processes.    In the 
immune system, regulation of endothelial cell-cell junctions is critical for passage of white 
blood cells from the blood to underlying tissue that may be damaged or infected.  If 
disassembly or reassembly is disregulated, you are left with either a weak immune response 
or a constitutive response associated with several inflammatory disorders such as arthritis.  
Another example of disregulated junctions is in epithelial-to-mesenchymal transition (EMT).  
As cells become transformed, they can lose expression of cellular adhesion molecules, 
resulting in loss of adhesion to matrix and to adjacent cells.  These transformed cells now 
have increased mobility and are able to travel to different sites (i.e. metastasis).  One way in 
which cell-matrix and cell-cell adhesions can be regulated is through the control of tyrosine 
phosphorylation levels of proteins at points of cell adhesions.  Protein tyrosine kinases (PTK) 
and protein tyrosine phosphatases (PTP) are responsible for balancing phosphotyrosine 
levels.  The focus of my work has been on the role of PTPs, DEP-1 in particular, in 
regulating cell-cell adhesions.  In the next several pages I will give you an overview of the 
regulation of cellular adhesions by classical PTPs.  
 
Regulation of cell adhesion by protein tyrosine phosphatases 
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Cell adhesion and migration are two tightly coupled processes critical to normal 
development and physiology.   Two types of adhesion are usually distinguished:  adhesion of 
cells to the underlying extracellular matrix (ECM) and adhesion between adjacent cells.  
Adhesions are more than simple physical links to the matrix or to other cells; they are also 
sites where signals are initiated, allowing cells to monitor their immediate environment.  
Prominent among the signaling pathways that emanate from adhesion sites are those 
involving protein tyrosine phosphorylation.  Tyrosine phosphorylation is a major post 
translational modification that regulates many signal transduction pathways involved with 
proliferation and differentiation, and in communication between adjacent cells and cell-
matrix interactions.  The differential tyrosine phosphorylation of cell adhesion molecules and 
their associated proteins is one means of altering the assembly and stability of adhesions.  
Phosphotyrosine levels reflect the balance between protein tyrosine kinases (PTKs) and 
protein tyrosine phosphatases (PTPs). 
PTPs were discovered several years after PTKs and have been studied less 
extensively.  However, the number of genes encoding PTPs rivals that of PTKs, suggesting 
that the functions of PTPs may be just as complex (1).  In addition, the diversity of 
phenotypes in knockout mice lacking various PTP genes demonstrates that many PTPs have 
non-redundant functions.  Although PTPs were first believed to behave as “housekeeping” 
proteins, terminating signaling pathways initiated by PTKs, it is now appreciated that PTPs 
can activate kinases and other enzymes by removing inhibitory phosphates, thus playing a 
more active role in signaling pathways.  Several families of PTPs have been identified, 
including classical PTPs, dual specificity PTPs, myotubularins, PTEN-related PTPs and 
aspartic acid-based PTPs (2).  I will focus primarily on the classical PTPs and their functions 
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in cell-matrix and cell-cell adhesions.  Classical PTPs contain a highly conserved catalytic 
domain with a critical cysteine sulfhydryl in the catalytic site.  They show considerable 
diversity in their other domains, allowing for variations in binding partners, localization, and 
function.  In humans, 38 classical PTPs have been identified and these fall into two groups, 
either transmembrane receptor-type PTPs (RPTPs) or cytoplasmic PTPs (2).  RPTPs contain 
extracellular domains often resembling adhesion receptors, a single transmembrane domain, 
and either single or tandem catalytic domains in the intracellular sequence.  Cytoplasmic 
PTPs consist of a single catalytic domain with various amino- or carboxy- terminal protein-
binding motifs such as SH2 or FERM domains.  The diversity in structure of the non-
catalytic domains of PTPs determines their classification into subgroups and can affect 
variations in binding partners, localization and function. 
 
 
1. Cell-Matrix adhesion 
 
 PTPs and adhesion to extracellular matrix 
Transmembrane receptors of the integrin family are responsible for adhesion to many 
different ECM proteins, including fibronectin, laminin and collagen (3).  For cells in tissue 
culture, sites of strong adhesion to the ECM are known as focal adhesions and they serve to 
anchor bundles of microfilaments (stress fibers) to the plasma membrane via integrins.  Focal 
adhesions not only play a structural role, but also act as scaffolds for numerous signaling 
pathways downstream from integrin-mediated adhesion.  Prominent among these signals is 
tyrosine phosphorylation of proteins at the cytoplasmic face of focal adhesions catalyzed by 
PTKs such as FAK and Src family kinases (SFKs) (4).  Engagement of integrins in itself is 
 4
insufficient to induce the tyrosine phosphorylation and activation of FAK; integrin clustering 
at focal adhesions is required (5).  The aggregation of integrins and resulting tyrosine 
phosphorylation at these sites is driven by myosin dependent cytoskeletal forces.  This is, in 
turn, stimulated by the RhoA/Rho kinase pathway or pathways activating myosin light chain 
kinase (6).  During integrin-induced adhesion, in parallel with the activation of FAK and 
SFKs, there is a general inhibition of PTP activity (7). 
In comparison with the large amount known about the role of PTKs in focal 
adhesions, much less is known about PTPs.  Several studies have reported changes in 
tyrosine phosphorylation within focal adhesions in response to manipulating specific PTPs.  
However, the identification of PTP targets within focal adhesions has been difficult and 
sometimes contradictory.  The problem arises because tyrosine phosphorylation is important 
not only as a consequence of integrin-mediated adhesion, but it is also involved in many 
upstream signaling pathways that affect integrin clustering and focal adhesion assembly.  
Consequently, it is often difficult to discern whether manipulation of a PTP is directly 
affecting the phosphorylation of a protein downstream from integrins, or whether it is 
affecting focal adhesion assembly or disassembly, and thereby indirectly affecting tyrosine 
phosphorylation of focal adhesion components.  Strategies used for investigating the roles of 
specific PTPs have included over-expression of wildtype PTPs, expression of mutant or 
catalytically dead PTPs and elimination of specific PTPs, either by knockout or siRNA 
strategies.  However, all of these approaches may influence upstream signaling, and can be 
misleading when the readout is the tyrosine phosphorylation of focal adhesion components.  
One of the best approaches to identify specific targets is to use catalytically dead PTPs to 
“trap” their substrates (8). 
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PTPs can affect integrin-mediated adhesion and the tyrosine phosphorylation that 
occurs in focal adhesions by acting at least at three different levels. They can affect signaling 
upstream, for example, by regulating the activities of GEFs and GAPs for Rho proteins; they 
can act proximal to integrin engagement, for example by regulating Src kinase activity; or 
they can dephosphorylate downstream targets, some of which may feedback to influence 
upstream signaling pathways affecting focal adhesion assembly and turnover. 
 
Upstream regulation of Rho protein activity by protein tyrosine phosphatases: PTP-PEST, 
Shp-2 and LMW-PTP  
Important upstream regulators of cell matrix adhesions are members of the Rho 
family of small GTPases (9).  In humans, this family of regulatory proteins includes 
approximately 20 proteins, although most work has been focused on three ubiquitously 
expressed members, RhoA, Rac1 and Cdc42.  Like other G proteins, these proteins are active 
in the GTP-bound form and are inactive when GTP is hydrolyzed to GDP.  Activation of Rho 
proteins is catalyzed by guanine nucleotide exchange factors (GEFs) which stimulate 
exchange of bound GDP with GTP from the cytoplasmic pool.  Most Rho proteins have 
intrinsic GTPase activity, which is further stimulated by GTPase activating proteins (GAPs).  
Many GEFs and GAPs are regulated by tyrosine phosphorylation.  Consequently, PTPs can 
profoundly influence the cycle of Rho protein activation by regulating the state of 
phosphorylation of GEFs and GAPs (Figure 1.1).  Examples of PTPs that have been reported 
to regulate Rho protein activity are given in Table 1.  
PTP-PEST is one PTP that affects adhesion and migration, in part by regulating the 
activity of Rho proteins.  Over-expression of PTP-PEST depresses membrane ruffling at the  
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Figure 1.1.  PTP regulation of integrin-mediated adhesion signaling and focal adhesions.  Upstream, the 
clustering of integrins is determined by RhoA-GTP levels (activity).  PTPs can regulate the activity of Rho 
proteins by controlling the phosphorylation states of GEFs and GAPs.  Downstream, integrin clustering leads to 
SFK and FAK activation.  PTPs can both activate and inhibit SFKs by removing inhibitory or activating 
phosphorylations.  Regulating the tyrosine phosphorylation of downstream targets such as FAK regulates the 
dynamics and disassembly of focal adhesions.  
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Table 1.  Regulation of Rho-GTPase activity by PTPs 
 
PTP 
GTP LEVEL       TARGET CITATION    
Shp-2 ↑ RhoA-GTP 
↑RhoA-GTP 
↓RhoA-GTP 
p190RhoGAP 
Unknown 
Vav, Vav2 
(12) 
(13*, 14) 
(15, 16*) 
PTP-PEST ↓Rac1-GTP 
 
Unknown GEF (10) 
 
LMW-PTP ↑RhoA-GTP p190RhoGAP (17) 
* implied from phenotype, GTP levels not measured 
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leading edge of cells due to decreased Rac1 activity (10).  Conversely, in PTP-PEST-/- cells 
Rac1 activity is elevated and sustained in cells plated on fibronectin (11). 
Several pathways by which PTP-PEST might regulate Rac activity are suggested 
from published studies. PTP-PEST has been shown to bind and act on both p130Cas and 
paxillin (18, 19) (Table 2).  Both of these proteins, when tyrosine phosphorylated, interact 
with Rac GEFs.  Tyrosine phosphorylated p130Cas and paxillin bind the adapter Crk (20-
22), which in turn recruits the Rac GEF DOCK180 (23, 24). In addition, paxillin binds the 
Rac GEF PIX via the adapter protein Pkl/Git (25).  Therefore, a loss of PTP-PEST may 
increase Rac activity by increasing the pool of phosphorylated p130cas and paxillin, thus 
preserving their interactions with and regulation of their GEF binding partners.  Recent work 
has revealed that trapping mutants of PTP-PEST also bind Vav2 (11), a ubiquitously 
expressed GEF regulated by tyrosine phosphorylation (26). This observation raises the 
possibility that PTP-PEST may directly regulate Rac activity by controlling the 
phosphorylation state of this GEF without the need for adaptor proteins such as 
p130cas/paxillin. 
The increased Rac1 activity found in PTP-PEST-/- fibroblasts would be predicted to 
increase migration, but these cells actually have reduced migration rates (27).  Examination 
of cell morphology reveals prominent ruffling membranes/lamellipodia (hallmarks of active 
Rac1), but the cells develop elongated tails, indicative of problems in detaching from the 
substrate (11).  Elongated tails are often associated with low RhoA activity (28).  Through 
interactions with both a Rac GEF and an as yet unidentified Rho GAP, PTP-PEST may 
regulate the activities of both GTPases, thereby influencing migration by controlling 
membrane ruffling and tail retraction.  However, an inability to disassemble focal adhesions  
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Table 2.  Binding partners and substrates for PTPs involved in regulating cell-matrix 
adhesion 
PTP BINDING PARTNERS SUBSTRATES 
SHP-2 SHPS-1 (29, 30) FAK (31) 
SHPS-1 (29, 30) 
PAG (32) 
Src (30) 
Vav2 (16) 
p190RhoGAP (12) 
PTPα Src-family kinases (33) 
αvβ3 integrins (34) 
 
Src (35, 36) 
Fyn (35) 
Yes (33) 
PTP1B p130cas (37) 
β1 integrins (38)  
 
P130cas (37) 
Src (39) 
PTP-
PEST 
P130cas (19)  
Paxillin (18) 
csk (40)  
 
 
P130cas (19)  
Paxillin (18) 
PYK2/CAKβ (41)  
Vav2 (10) 
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in the rear would also account for the phenotype of the PTP-PEST null cells.  Focal adhesion 
disassembly is regulated by tyrosine phosphorylation as  well and will be discussed below.  
These results point to the complexity of phenotypes generated by PTP knockouts due to the 
actions of PTPs on multiple targets. 
Another PTP implicated in regulating Rho protein activity is Shp-2.  Here, conflicting 
results have been obtained, with some groups reporting that Shp-2 inhibits RhoA activity (15, 
16), while other groups find that Shp-2 stimulates RhoA activity (13, 14), and still others 
suggest that Shp-2 can exert both positive and negative regulatory effects on RhoA activity 
(42).  One target for Shp-2 is p190RhoGAP, a widely expressed GAP for RhoA (43) (Table 
2).  The activity of p190RhoGAP is stimulated by tyrosine phosphorylation (12, 43).  By 
dephosphorylating p190RhoGAP and so suppressing its GAP activity, Shp-2 can elevate 
RhoA GTP levels (i.e. activate RhoA).  Paradoxically, Shp-2 is one of the PTPs that 
stimulates Src activity (see below), and Src is responsible for phosphorylation and activation 
of p190RhoGAP (44).  Consequently, Shp-2 can act on both sides of the phosphorylation 
equation regulating p190RhoGAP activity.   In addition, Shp-2 may be one of the PTPs that 
inactivates Rho GEFs that are regulated by tyrosine phosphorylation (15, 16).  Thus, the 
apparently conflicting role of Shp-2 with regards to RhoA activity could be reconciled by the 
differential action of the PTP on targets that can either positively or negatively regulate 
RhoA activity. 
One non-classical PTP that warrants mentioning in the context of RhoA activity is 
LMW-PTP.  It has been reported to act downstream of Src to regulate the phosphorylation 
state of p190RhoGAP, thereby controlling Rho-mediated cytoskeletal rearrangement (45). 
LMW-PTP has also been implicated in the crosstalk between Rac1 and RhoA, in which Rac1 
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mediated generation of reactive oxygen species was observed to inhibit LMW-PTP.  This 
elevated p190RhoGAP tyrosine phosphorylation and activity, suppressing RhoA activity 
(17).   
 
PTPs acting proximal to integrins: Shp-2, PTPα, and PTP1B 
What is the initiating signal downstream from integrin-mediated adhesion?  Several 
studies have implicated Src family kinases (SFKs) in some of the earliest steps downstream 
from integrins and preceding the activation of FAK (44, 46, 47). SFKs have been shown to 
bind β-integrin cytoplasmic domains (48, 49), which has prompted investigation into how 
these kinases are regulated in response to interaction of the integrins with their ligands.  
SFKs are held in an inhibitory state by two intramolecular interactions.  One interaction 
involves the SH3 domain binding to the linker region between the kinase and SH2 domains.  
This constraint may be removed by association of the SFK with integrin cytoplasmic 
domains (39). The second intramolecular constraint to SFK activity involves binding of the 
SH2 domain to the phosphorylated C-terminal tyrosine residue (Y527 in avian, Y529 in 
mammalian cells).  This inhibitory phosphorylation of Src is catalyzed by C-terminal Src 
kinase (Csk).  Csk complexes with Src and inactive integrin αIIb/β3 (49).  A PTP must 
dephosphorylate the C-terminal tyrosine in order for SFK activation.  In addition, for full 
activity, phosphorylation of Y416 must occur in the activation loop within the kinase 
domain.   Activation by removal of the C-terminal phosphate raises the possibility that PTPs 
may be involved in the initiation of the signaling downstream from integrin engagement or 
clustering.  Several PTPs are capable of activating SFKs and, in the context of integrins, 
three have been studied, Shp-2, PTPα, and PTP1B (30, 31, 33, 36, 39).  
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Cells expressing a truncated form of Shp-2 (lacking the N-terminal SH2 domain), 
reveal diminished activation of Src and elevated phosphorylation of the inhibitory site, Y529, 
in response to adhesion to ECM (30, 32).  These cells spread more slowly and display 
reduced tyrosine phosphorylation of FAK, paxillin and p130Cas (30, 31).  In addition, Shp-2 
may indirectly regulate Src activity by regulating the recruitment of Csk to the membrane.  
Csk is recruited to the membrane via association with tyrosine phosphorylated PAG 
(phosphoprotein associated with glycosphingolipid-enriched microdomains), a 
transmembrane glycoprotein.  Shp-2 dephosphorylates PAG and abolishes the Csk binding 
site, resulting in a reduction in membrane associated Csk and a reduction of Csk-mediated 
Src inhibition (32).  Thus Shp-2 may activate Src both by directly acting on its C-terminal 
phosphorylation site and by inhibiting Csk recruitment.  A protein that may act in parallel to 
PAG is SHPS-1 (SIRPα1).  Like PAG, SHPS-1 recruits Shp-2 to the membrane and is a 
target for its activity (29, 30). 
PTPα is a receptor type, transmembrane PTP involved in the activation of SFKs and 
in integrin signaling pathways.  Ectopic expression of PTPα enhances the dephosphorylation 
of the c-terminal Y529, strongly activating src and fyn kinases (36).  Cells lacking PTPα 
spread more slowly and contain decreased tyrosine phosphorylation of focal adhesion 
components (35, 50).  The decrease in tyrosine phosphorylation of FAK, especially at 
autophosphorylation site Y397, in PTPα-/- cells suggests that this phosphatase lies between 
integrins and the activation of FAK (51).  PTPα and the integrin αvβ3 co-immunoprecipitate 
from cells spreading on ECM substrates (34).   This association has been shown to be 
involved in the activation of SFKs following integrin engagement, which, in turn, is involved 
in the reinforcement of integrin-cytoskeletal forces in response to tension (34).  In this study, 
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the SFK involved was Fyn rather than Src.  No evidence for an interaction between β1 
integrins and PTPα was seen, but because similar downstream responses are observed for β1 
and β3 integrins, it seems likely that parallel pathways may operate, possibly involving 
different PTPs and different SFKs.  
In platelets, activation of Src occurs rapidly in response to integrin engagement, 
whereas FAK activation is a relatively late event (46).  The association of Src with the β3 
cytoplasmic domain involves binding via its SH3 domain, relieving one of the inhibitory 
constraints on Src (39).  With platelet αIIb/β3, the activation involves release of associated 
Csk from the integrin/SFK complex and the subsequent recruitment of PTP1B.  Interestingly, 
the recruitment of PTP1B requires tyrosine phosphorylation of PTP1B and is blocked by Src 
inhibitors (39).  This implies that some level of Src activation must precede the recruitment 
of PTP1B.  Shattil and colleagues propose a model in which binding of αIIb/β3 to fibrinogen 
induces micro-clustering of αIIb/β3, juxtaposing Src molecules so that these cross-
phosphorylate on Y416.  It is suggested that this results in initial activation sufficient to 
phosphorylate and recruit PTP1B, which, by removing the C-terminal phosphorylation of Src 
results in full activity.  In this model, many of the subsequent tyrosine phosphorylations, 
including FAK activation, are triggered downstream from these initial events (39).  
 
Differential PTP1B signaling in various cell types 
With regard to its role in ECM adhesion, conflicting results have been reported for 
PTP1B.   The finding that PTP1B binds and acts on p130Cas (37) led to experiments 
investigating the effects of expressing wildtype or mutant forms of PTP1B unable to bind to 
p130Cas in cell adhesion situations.  Expression of wildtype but not mutant PTP1B slowed 
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fibroblast spreading and depressed tyrosine phosphorylation of p130Cas and other proteins in 
response to adhesion (52).  In addition, the expression of wildtype PTP1B enhanced the 
assembly of focal adhesions with short thick stress fibers, and decreased cell migration.  
Consistent with these findings, depressing PTP1B expression in vascular smooth muscle 
enhanced tyrosine phosphorylation of p130Cas and stimulated migration (53).  Seemingly 
contradictory results, however, were obtained in another study in which wildtype or 
catalytically dead PTP1B were expressed in L cells (38).  In these experiments, expression of 
the wildtype PTP1B did not depress tyrosine phosphorylation in response to adhesion to 
fibronectin, whereas expression of a catalytically dead mutant did.  Expression of the inactive 
mutant also suppressed Src activity and depressed cell attachment to a fibronectin 
substratum.  Additionally, the cells expressing the mutant PTP1B displayed an elongated 
morphology, with focal adhesions that were reduced in size and number.  A third study 
examined the behavior of fibroblasts derived from PTP1B null mice (54).  In this work, the 
cells lacking PTP1B exhibited delayed spreading on a fibronectin-coated surface, but 
surprisingly little effect was found in terms of tyrosine phosphorylation in response to 
adhesion to fibronectin.  However, when wildtype and PTP1B null cells were transformed 
with SV40Tag, effects on tyrosine phosphorylation were seen.  Now the transformed null 
cells exhibited decreased tyrosine phosphorylation of p130Cas relative to transformed 
wildtype cells following short periods (20 min) of adhesion to fibronectin.  These null cells 
also showed hyperphosphorylation of the inhibitory site in Src (Y527) in some situations.  
Notably, the SV40Tag-transformed fibroblasts revealed an increased expression of PTP1B 
relative to primary mouse embryo fibroblasts, possibly accounting for the differences 
between the transformed and primary cells. 
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Can these apparently conflicting observations with PTP1B be reconciled?  As the 
authors have suggested, cell type differences may be critical, especially given that SV40Tag-
transformed cells elevate expression of PTP1B (54).  Cell types may also diverge both as to 
where PTP1B is acting in adhesion signaling pathways and in the degree of compensation by 
other PTPs.  For example, in some cell types PTP1B may have a major role regulating the C-
terminal inhibitory phosphorylation site of SFKs, whereas in other cell types different PTPs 
(e.g. PTPα or Shp-2) may be more important.  P130cas is a major substrate for Src and so in 
cells in which PTP1B is regulating Src activity, one would predict lower phosphorylation of 
p130Cas when PTP1B is absent or inactive (38, 54).  However, in other cell types where 
different PTPs may be more critical in regulating SFK activity, the effect of depressing 
PTP1B activity would be predicted to be less significant in terms of p130Cas 
phosphorylation.  Since PTP1B can also dephosphorylate p130Cas, it would not be surprising 
in these cells to observe that over-expression of wildtype PTP1B decreases the 
phosphorylation of this target protein (52).   One of the striking observations from Chernoff’s 
group is that the cells over-expressing PTP1B revealed enhanced focal adhesions and stress 
fibers (52).  This is suggestive of increased RhoA activity and could arise because of 
dephosphorylation and inactivation of a regulatory protein such as p190RhoGAP.  However, 
this phenotype could also result from defective focal adhesion disassembly (see below). 
 
Focal adhesion disassembly: Downstream regulation by PTPs 
With the discovery of FAK activation in response to integrin-mediated adhesion, it 
was widely interpreted that tyrosine phosphorylation promoted focal adhesion assembly.  
However, the phenotype of FAK knockout cells, as well as cells in which FAK was displaced 
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from focal adhesions, revealed robust and stable focal adhesions in the absence of FAK and 
tyrosine phosphorylation detectable by immunofluorescence (55, 56).  Rather than assembly 
of focal adhesions, FAK activity correlated with focal adhesion turnover and disassembly (4).  
While several pathways downstream of FAK could contribute to  focal adhesion disassembly 
(4, 25, 57-61), a novel, endocytic pathway (62) suggests a potentially important role for an as 
yet unidentified PTP.   In this work, tyrosine phosphorylated FAK was found to recruit 
dynamin to focal adhesions (62).  Dynamin is a protein involved in endocytosis and 
expression of a dominant negative form of dynamin that inhibits endocytosis blocked focal 
adhesion disassembly.  The association of FAK with dynamin is mediated by the adaptor 
protein Grb2, which binds to phosphorylated Y925 in FAK and to the proline rich region of 
dynamin.  Expression of the non-phosphorylatable FAK mutant, Y925F, failed to rescue 
focal adhesion disassembly in FAK null fibroblasts (62). 
Identification of the PTP that removes the phosphate from Y925 in FAK will be 
important.  Based on the above information, it would be predicted that this PTP would have a 
key role in regulating focal adhesion disassembly and, by extension, in regulating cell 
migration.  In order for cells to migrate, focal adhesions must be disassembled so that strong 
adhesions to the underlying ECM can be released.  The PTP that mediates dephosphorylation 
of Y925 in FAK would be anticipated to increase focal adhesion stability and decrease 
migration when it is over-expressed, but to increase migration rates and the turnover of focal 
adhesions when it is inhibited or knocked out.  This phenotype matches that described by Liu 
and coworkers when they over-expressed PTP1B in fibroblasts (52) and it will be interesting 
to learn whether PTP1B or another PTP regulates the phosphorylation status of Y925 in 
FAK. 
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2. Cell-Cell adhesion 
 
PTPs and cell-cell junctions 
Epithelial tissues typically display stable cell-cell adhesion that is accompanied by prominent 
cell junctions between interacting cells.  Tight junctions (TJs) are responsible for the barrier 
function of many epithelia, whereas adherens junctions (AJs) and desmosomes mediate 
strong intercellular adhesion.  The assembly and function of TJs is typically dependent on the 
state of AJs, so that modulating AJ function often affects TJ barrier properties.  The major 
adhesion molecules in both AJs and desmosomes belong to the cadherin family; however, 
cadherins can also contribute to adhesions between cells where distinct junctions do not 
develop and where adhesion is more dynamic.  Additional adhesion molecules, such as 
nectins (63), are also present in AJs, but we will focus here on cadherins.  Whereas the 
extracellular domain of cadherins participates in calcium-dependent homophilic adhesion, the 
cytoplasmic domain binds p120ctn and β-catenin (64-66).  The former regulates the stability 
of cadherins on the cell surface (67), and β-catenin provides a link to α-catenin and the actin 
cytoskeleton, although the details of the bridge remain controversial (68).  Tyrosine 
phosphorylation of cadherins and their associated proteins has major effects on the stability 
of adherens junctions (69, 70).  In early work, it was shown that inhibiting PTPs with 
pervanadate elevated tyrosine phosphorylation in adherens junctions and promoted the 
disassembly of these structures (71).  However, the same group later observed that in some 
situations elevation of tyrosine phosphorylation first transiently stimulated AJ assembly 
before resulting in the eventual disassembly of the same structures (72).  Activation of PTKs 
or inhibition of PTPs can lead to increased tyrosine phosphorylation of members of the 
cadherin-catenin complex, dissociation of the AJ from the cytoskeleton and disruption of 
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cell-cell adhesion (73-75).  For example, phosphorylation of tyrosine residues 755 and 756 
on E-cadherin leads to its ubiquitination and subsequent endocytosis, resulting in loss of 
junctional integrity (76).  Similarly, phosphorylation of Y658 and Y731 in the cytoplasmic 
domain of VE-cadherin prevents binding of p120ctn and β-catenin, respectively, and causes a 
decrease in barrier function (77).  Therefore, maintenance of junctional integrity is regulated 
in part by reversible tyrosine phosphorylation that results from a competing balance of PTK 
and PTP activity.  Receptor-PTPs such as PTPµ, DEP-1, and VE-PTP, as well as the 
cytosolic PTPs, PTP1B and Shp-2, have been shown to bind to members of the cadherin-
catenin complex  (78-83) (Table 3) and to regulate cell-cell adhesion by means of regulating 
phosphorylation of the cadherin-catenin complex. 
 
Direct regulation of the cadherin-catenin complex 
The extracellular domains of PTPμ can mediate cell-cell adhesion via homophilic 
interactions (84, 85). Together with its binding to p120ctn and the cytoplasmic domain of 
cadherins, the homophilic interactions of PTPμ  combine to localize it to cell-cell junctions 
(78, 79, 86, 87).  Localization at AJs orients PTPμ’s catalytic domain in close proximity with 
substrates VE-cadherin and p120 catenin (79, 87).  In addition, knockdown of PTPμ by 
siRNA increases permeability of endothelial monolayers demonstrating its role in the 
regulation of junctional integrity (87).  Although many of the effects of PTPμ at AJs are 
undoubtedly due to its phosphatase activity, other domains of the protein may also contribute 
to junctional stability.  Evidence for this came from a   
study of prostate carcinoma cells lacking endogenous PTPμ which were unable to form AJs 
even though E-cadherin and the catenin proteins were present.  Expression of PTPμ restored 
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cadherin-mediated cell-cell adhesion, but strikingly this could also be achieved by expression 
of catalytically dead PTPμ (88).  This finding suggests that PTPμ can act as a scaffold and 
recruit additional regulatory proteins to sites of cell-cell adhesion. 
Another PTP important for junction formation and maintenance is high cell density 
enhanced PTP-1 (DEP-1).  Expression of DEP-1 is increased more than ten-fold in many cell 
types as they approach confluence, suggesting it contributes to cell-cell adhesion and contact 
inhibition of growth (89).    DEP-1 is present at the apical surface of endothelial cells, but 
also co-localizes with VE-cadherin at intercellular junctions (90, 91).  DEP-1 indirectly 
associates with VE-cadherin by binding to p120ctn, γ-catenin (plakoglobin) and β-catenin 
(Table 3); DEP-1 regulates their phosphorylation state, preserving their interactions with the 
cadherins, and promoting cell-cell adhesion (80, 90).  The role of DEP-1 in organizing cell-
cell junctions is supported by the observation that in cells lacking strong cell-cell adhesion, 
such as fibroblasts, overexpression of DEP-1 results in a change in localization of cadherins 
from discrete areas of cell-cell contact to large areas reminiscent of continuous AJ found in 
epithelial cells (92).   
 A PTP in the same family as DEP-1 is vascular endothelial PTP (VE-PTP), which is 
selectively expressed in endothelial cells, and binds to VE-cadherin but not to β-catenin (93).  
VE-PTP associates with VE-cadherin via its membrane-proximal extracellular domain and its 
recruitment results in the dephosphorylation of VE-cadherin (81).  Expression of wild type 
VE-PTP decreases paracellular permeability in endothelial monolayers, while the 
catalytically inactive mutant has no effect, indicating that the phosphatase activity of VE- 
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Table 3.  Binding partners and substrates for PTPs involved in the regulation of cell-cell 
junctions 
 
PTP BINDING PARTNERS SUBSTRATES 
PTPμ E cadherin (78) 
PTPμ (84, 94) 
 RACK-1 (95) 
p120ctn (79) 
VE-cadherin (87) 
p120ctn (79) 
VE-cadherin (87) 
PTPκ PTPκ (96) 
β-catenin, plakoglobin (97) 
β-catenin (97) 
PTP-LAR β-catenin (98, 99) 
plakoglobin (99) 
β-catenin (99) 
DEP-1 p120ctn (80) 
Matrigel component (100) 
p120ctn, β-catenin, 
plakoglobin (80) 
VE-PTP VE-cadherin (81) VE-cadherin (81) 
 
SHP-2 β-catenin (82)  
PECAM (101, 102)  
β-catenin (82) 
PTP1B N-Cadherin (83, 103, 104) β-catenin (83, 103, 104) 
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PTP acting on VE-cadherin is necessary for maintaining the integrity of endothelial junctions 
(81). 
Cytosolic PTPs such as PTP1B and Shp-2 have also been implicated in regulating 
cell-cell adhesion by controlling phosphorylation of cadherin/catenin proteins (82, 83, 103).  
PTP1B binds directly to the cytoplasmic domain of N-cadherin, an interaction that promotes 
β-catenin binding and targeting of the cadherin/catenin complex to the cell membrane (104).  
Expression of a catalytically inactive mutant of PTP1B disrupts cadherin-mediated adhesion, 
with concomitant increases in tyrosine phosphorylation of β-catenin and reduction in the 
association of N-cadherin with the actin cytoskeleton, suggesting that the catalytic activity of 
PTP1B is important for junctional maintenance (83, 103).  Shp-2 is another cytosolic PTP 
associated with the cadherin/catenin complex in confluent endothelial cell monolayers, 
specifically interacting with β-catenin (82).  Thrombin treatment of endothelial cells induces 
Shp-2 tyrosine phosphorylation and dissociation from β-catenin followed by junctional 
breakdown and the formation of large intercellular gaps, thus supporting the hypothesis that 
Shp-2 localization to junctions also helps maintain endothelial junctional strength and 
integrity (82).  The loss of Shp-2 binding is accompanied by an increase in phosphorylation 
of β-catenin, plakoglobin and p120ctn.  AJs are not the only adhesive complexes where PTPs 
play a role in regulating signal transduction.  Shp-2 binds to platelet endothelial cell adhesion 
molecule-1 (PECAM-1) (101, 102) and intercellular adhesion molecule 1 (ICAM-1) (105, 
106).  In response to ICAM-1 engagement, phosphorylated ICAM-1 binds to Shp-2 and this 
interaction is necessary for Src activation as well as p38 MAPK activation (106).   
The concentration of PTPs, both cytosolic and transmembrane, at AJs indicates the 
importance of maintaining low levels of tyrosine phosphorylation at these sites, except when 
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the junctions need to be remodeled or disassembled.  In general, the suppression of bulk PTP 
activity by inhibitors or the suppression of individual PTPs by siRNA elevates the tyrosine 
phosphorylation of cadherins and their associated proteins.  In turn, this results in 
destabilization of the junctions and diminished epithelial or endothelial barrier functions.  
 
Rho GTPases and cell-cell adhesion 
Just as with cell-matrix adhesions (107), there is bidirectional interplay between Rho 
family GTPases and cell-cell adhesions.  Not only is the assembly of AJs affected by the 
activities of Rho proteins, but cell-cell adhesion can stimulate or depress the activities of 
these G proteins, suggesting complex feedback loops.  Several studies have shown that Rac1 
activation promotes assembly of epithelial AJs and inhibition of either Rac1 or RhoA activity 
results in disassembly (108-110).  Conversely, other studies show that high levels of active 
Rac1 or RhoA can actually disrupt both TJs (111) and AJs (112, 113); this might reflect 
different cellular contexts or the need for tight regulation of GTPase activity.  The formation 
of AJs can activate Rac1 and Cdc42 (114, 115) but inhibit RhoA (115).  PTPs may play 
critical roles in these upstream and downstream pathways by regulating the phosphorylation 
and activity of GTPase activating proteins (GAPs) and guanine nucleotide exchange factors 
(GEFs) (107).  For example, p190RhoGAP tyrosine phosphorylation was implicated in the 
depression of RhoA activity downstream from cadherin engagement (116). 
With endothelial monolayers, several agents that promote increased permeability also 
stimulate Rac1 activity.  PTPs are also likely to be important in this response to Rac1 
because in these cells Rac1 has been shown to generate reactive oxygen species (ROS) (117).  
In turn, ROS are potent inhibitors of PTPs (118) and are responsible for the elevation in 
junctional protein tyrosine phosphorylation that results from Rac1 activation (113, 117, 119).  
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Regulation of PTP activity  
The resemblance of the extracellular domains of RPTPs to cell adhesion molecules 
has stimulated a search for potential binding partners and by extension, for modes of 
regulation via such interactions.  Several mechanisms for modulation of specific PTP activity 
exist (Figure 1.2).  In some cases, homophilic interactions have been detected, as first shown 
with PTPµ (84, 85).   Two closely related PTPs, PTPκ and PTPλ, have similarly been shown 
to interact in a homophilic manner (96, 120).  The extracellular domains of several RPTPs 
participate in heterophilic interactions with ECM or other components.  For example, LAR 
binds the laminin/nidogen complex, which is prominent in many basement membranes (121).  
Similarly, PTPσ binds to heparin sulfate proteoglycans (122) and PTPα binds contactin (123 
).  Although several interactions involving the extracellular domains of RPTPs have been 
identified, in most cases no effect on the activity of the PTP has been demonstrated.  One 
exception is the interaction of PTPβ/ξ  with pleiotrophin, which inhibits PTP activity and 
results in an increase in β-catenin phosphorylation (124).  Pleiotrophin is a heparin binding 
growth associated molecule and its interaction with PTPβ/ξ promotes cortical neuron 
migration (124).  In  
contrast, DEP-1 phosphatase activity is up-regulated by the binding of its extracellular 
domain to an unknown component of Matrigel® (100).  The observation that the activities of 
RPTPs can be regulated by the interactions of their extracellular domains will be broadly 
important if further work can establish that this is a general characteristic of RPTPs.  It is 
easy to imagine many scenarios in which tyrosine phosphorylation levels could be regulated 
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by interactions of the extracellular domains of RPTPs with other cells, with matrix molecules 
or soluble ligands (Figure 1.2A). 
Dimerization of RPTPs provides another potential mode of regulating their activity.  
RPTPs have traditionally been considered to be inactive when dimerized and active when 
monomers (125).  This idea was first proposed when a chimera of the extracellular domain of 
EGFR fused to the intracellular domain of CD45 was inhibited by EGF-induced dimerization 
(126).  Further support was generated when studies revealed RPTPα exists as dimers on the 
cell surface, and that this dimerization inhibits the activity of the phosphatase via an 
interaction of the tandem catalytic domains, preventing the binding of substrates (127-129).  
This suggests a model where RPTPs exist as inactive dimers on the cell surface in the 
absence of a ligand and binding of the ligand dissociates the dimers and activates the PTP 
(Figure 1.2B).  However, dimerization-induced inactivation of RPTPs through blockage of 
the active site by an opposing PTP domain may not be a universal mechanism.  Structural 
analysis of the membrane-proximal catalytic domain of PTPµ and the entire cytoplasmic 
domain of PTP-LAR suggests that these PTPs are not inhibited by dimerization (130, 131).  
In addition, RPTPs such as DEP-1 and VE-PTP contain a single catalytic domain and 
therefore may also not be inhibited by dimerization. 
 The regulation of PTP activity by ROS is an area developing very rapidly and too 
large to review in detail here.  The cysteine residue in the catalytic site of classical PTPs has 
long been known to be sensitive to oxidation and this has been the basis for broad specificity 
inhibitors, such as H202 and pervanadate.  Subsequent work has shown that reversible 
oxidation of the catalytic cysteine can provide a physiological mechanism for regulating 
PTPs (118) (Figure 1.2C).  The generation of ROS was originally identified as a defense  
 25
 
 
 
 
Figure 1.2.  Modes of regulation of receptor protein tyrosine phosphatase activity.  (a) RPTPs bind soluble 
ligands (D,E) or interact in trans with proteins on adjacent cells by either a homophilic (A) or heterophilic (B,C) 
mechanism.  In some instances, such as homophilic interaction, it is not clear whether the interaction affects 
activity (shown with a yellow cytoplasmic domain).  However, heterophilic interactions can be either activating 
(shown in green) or inhibitory (shown in red) and appear to be ligand/PTP specific.  (b) RPTPs also interact in 
cis on the cell surface.  In most cases dimerization is associated with inactive PTPs.  However, the known 
conformational change by which dimerization inhibits activity is not consistent for the interactions of all 
RPTPs.  Therefore, in some cases dimerization may increase PTP activity.  Further investigation into this is 
needed.  (c) In several cell types reactive oxygen species (ROS) are generated in signaling pathways, such as 
downstream from Rac1 activation.  The reversible oxidation of the catalytic cysteine by ROS inhibits PTP 
activity.   
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mechanism in the phagocytic killing of bacteria by leukocytes, but more recently the 
generation of low levels of ROS by other cells has been recognized as a widespread 
occurrence with important physiological consequences (132).  The formation of ROS is 
downstream of active Rac1 (17, 117).  For example, in endothelial cells, active Rac1 
promotes endothelial permeability and is associated with increased tyrosine phosphorylation 
of junctional proteins, such as VE-cadherin and β-catenin (117, 119).  These effects are 
blocked by inhibiting the generation of ROS and are mimicked by pervanadate (117).  
Whether these effects are the result of one or a few PTPs being inhibited or reflect broad 
inhibition of all PTPs within these cells has not been established.  It will be interesting to 
determine the degree to which ROS can act locally on one or a few PTPs rather than globally 
by inhibiting all PTPs within a cell.  Techniques have been developed for analyzing the 
reversible oxidation of PTPs (133) and so this area should advance rapidly.  There are many 
physiological situations in which Rac1 is activated and it will be important to determine 
whether the generation of ROS and the consequent inactivation of PTPs is a general signaling 
pathway downstream from Rac1 or whether this only occurs in particular situations.   
 
 
DEP-1 (density enhanced protein tyrosine phosphatase-1) 
 
As mentioned above, there are both cytoplasmic and receptor protein tyrosine 
phosphatases.  This thesis focuses on the role of RPTPs in general and DEP-1 in particular, in 
regulating cell-cell adhesion and signaling events.  Also known as PTP-η, PTPRJ, and 
CD148, DEP-1 is a single pass transmembrane protein with an extracellular domain 
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consisting of 8 fibronectin type III repeats, a transmembrane domain and a single 
intracellular catalytic domain (89, 134).  Classification of RPTPs is based on the sequence 
motifs of their extracellular domains (Fig. 1.3) and these characteristics classify DEP-1 as a 
type III RPTP (135).  Several reviews discuss the structural differences of all PTPs in more 
detail (2, 136-138).  DEP-1 protein levels were enhanced greater than 10 fold in fibroblasts 
as the cells were grown to high density, which led to its name density enhanced protein 
tyrosine phosphatase-1 and to the hypothesis that DEP-1 may be involved in mechanisms of 
cell differentiation and contact inhibition of growth (89).  This hypothesis has been supported 
by several studies in which increased expression of DEP-1 inhibited the growth of several 
cancer cells in vitro (139-142).  Originally DEP-1 was cloned out of a human cDNA library 
but homologues have been identified in rat and mouse (134, 143, 144) and DEP-1 is 
considered to be ubiquitously expressed (143). 
In the last decade the development of the substrate trapping mutant has helped to 
identify potential substrates of PTPs.  These trapping mutants are point mutations of key 
residues surrounding the active site important for enzyme-substrate recognition and catalytic 
activity (145-147). The conserved cysteine in the catalytic pocket responsible for the 
phosphor-enzyme interaction is mutated to a serine (C/S) creating a catalytically dead 
mutant.  This mutant retains some ability to bind to substrates but has most extensively been 
used as a catalytically dead mutant in studies examining phosphorylation of putative 
substrates.  In addition, the conserved aspartic acid in the WPD loop of the catalytic domain 
can be mutated to an alanine (D/A).  This mutation prevents the aspartic acid from acting as a 
general acid and facilitating the protonation of the oxygen atom in the tyrosyl leaving group 
and traps the substrate within the phosphatase’s catalytic domain (8). This mutation allows  
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Figure 1.3.  Structure of receptor protein tyrosine phosphatases.  RPTPs are divided into subcategories based on 
the structure of their extracellular domain.  Shown here the 5 most common types.  Blue ovals (FN), fibronectin 
type III repeats; dark blue Ig, Ig like domains; orange circle (CA), carbonyic acid; D1, first catalytic domain, 
often active, D2, second catalytic domain, often inactive, dark gray, transmembrane domain.  Adapted from (2). 
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for the binding of the phosphorylated substrate but prevent its removal, turning a transient 
interaction into a  
stable one.  Several substrates for DEP-1 have been identified using this trapping mutant, 
including p120 catenin, β-catenin, the p85 subunit of PI3K, and the HGF receptor Met (80, 
148, 149).  Physiological effects of these interactions still need to be elucidated, however, 
there is a great body of literature demonstrating DEP-1’s regulation of and involvement in 
several signaling pathways in different cell types and these will be reviewed in the following 
sections. 
  
Role of the extracellular domain of DEP-1 
The extracellular domain of DEP-1 is highly N-glycoslyated and believed to be acting 
as an adhesion receptor involved in outside-in signaling (89, 134). The intrinsic PTPase 
activity of DEP-1 may be regulated or modulated by interacting with other cell surface 
molecules (ligand mediated signal transduction) as well as through dimerization of DEP-1 
extracellular domains in cis.  When cells or recombinant DEP-1 protein were incubated with 
Matrigel®, a preparation of extracellular matrix proteins, DEP-1 catalytic activity increased 
(100).  The exact ligand that causes the increased catalytic activity is not known.  This was 
the first evidence of increased catalytic activity of a RPTP by an extracellular ligand.  A few 
years later, a research group developed an antibody to the extracellular domain of DEP-1 and 
tested its effect on endothelial cell growth (150).  They discovered that antibody-induced 
ectodomain oligomeriztion of DEP-1 inhibited cell growth by increasing the catalytic activity 
of the cytoplasmic domain (150).  This is particularly interesting due to the fact that other 
PTPs are believed to be inactivated when dimerized (126-129).  Therefore, dimerization of 
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DEP-1 or binding to extracellular proteins can increase PTP activity.  One proposed reason 
for the difference between other PTPs and DEP-1 is that DEP-1 has a single catalytic 
domain, not a tandem set of domains, and is not prone to the inhibitory binding of opposing 
PTP domains.   
It is also possible that the extracellular domain of DEP-1 is important independent of 
its ability to signal to its catalytic domain.  Mice with a knock-in mutation of DEP-1, where 
GFP replaced the intracellular catalytic domain, resulted in a dramatic embryonic lethal 
phenotype in homozygous mutants with mice dying before embryonic day 11.5 (91).  These 
mice had disorganized vascular structures and cardiac defects (91).  Interestingly, when the 
entire gene coding for DEP-1, PTPRJ, was deleted from mice they were viable, fertile and 
showed no gross anatomical alterations, suggesting PTPRJ is dispensable for normal growth 
and development of mice (151).  Therefore, loss of the protein had no effect but the presence 
of the extracellular domain (without PTP activity) is lethal.  This suggests that the 
extracellular domain of PTPRJ might act as functional ligand which is able to block 
pathways responsible for endothelial cell assembly necessary for correct vascularization 
(151).   
 
DEP-1 regulation of growth factor receptors 
A number of studies have examined DEP-1’s role in modulating growth factor signaling 
by directly acting on the growth factor receptors.  Knockdown of endogenous protein or 
expression of the catalytically dead mutant of DEP-1 in endothelial cells increased 
phosphorylation of VEGFR- 2 as well as p44/42 MAPK in response to VEGF, suggesting 
that DEP-1 negatively regulates VEGFR-2 activity (152).  Specific residues 
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dephosphorylated by DEP-1 have not yet been fully investigated for this RTK.  Biochemical 
studies both in vivo and using peptide substrates revealed that DEP-1 is able to directly 
dephosphorylate PDGF β-receptor in a site-selective manner (153). Interestingly, the 
regulatory Tyr 857 was not found to be a preferred site for DEP-1 dephosphorylation, instead 
Tyr 1021 showed the highest affinity for dephosphorylation (153).  Biological responses 
triggered by PDGF β-receptor and other PTKs is determined by the SH2 domain containing 
proteins that associate with receptor in a phosphorylation site selective manner (154, 155).  
Therefore, DEP-1 may not be attenuating the RTK signal completely by acting on the 
regulatory tyrosine but modulating the signaling output by dephosphorylation of a subset of 
SH2-domain binding tyrosines (153).    Similarly, HGF receptor kinase Met is also a 
substrate for DEP-1 with non-preferred targets in the tyrosines of the activation loop.  Instead 
DEP-1 dephosphorylates C-terminal tyrosines known to be important for morphogeneis and 
Gab1 binding (149).  Again, this result supports the role of DEP-1 in controlling the 
specificity of signals induced by the RTK rather than a simple “off switch”.  For these 
reasons, regulated activation and expression of PTPs is a possible mechanism for altering 
biological response following ligand stimulation of RTKs.    Interestingly, LMW-PTP (a 
structurally distinct PTP from DEP-1) is also able to dephosphorylate PDGF β-receptor but 
with the reverse preference for tyrosine residues (156).  This suggests that the preference for 
phospho-peptides of PDGF β-receptor by DEP-1 is not shared by other PTPs involved in 
PDGF β-receptor dephosphorylation and can provide an explanation for why several PTPs 
are able to act on the same substrate.   
Several studies have also investigated the physiological effects of DEP-1 on PDGF 
signaling through overexpression and knockdown studies.  DEP-1 expression in fibroblasts 
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inhibited PDGF-stimulated cell migration (92, 157), whereas DEP-1 -/- MEFs showed 
increased chemotaxis towards PDGF (158).  Several PDGF-stimulated signaling events were 
negatively modulated by DEP-1 expression, with the most prominent effects being on 
phospholipase Cγ1, Ras and ERK1/2 activation (157).  Another study also showed that the 
Ras-MAPK pathway as well as the PI3-kinase-Akt pathway was negatively regulated by 
DEP-1 protein levels (92).  Although these studies are in agreement with regards to signaling 
effects and migration, contradictory results have been found for the effect of DEP-1 on cell-
matrix adhesion.  Jandt et al. found that DEP-1 expression was a positive regulator of cell 
adhesion, with DEP-1 expressing cells initially adhering faster but eventually reaching the 
same number as control cells over a 4 hr period (157).  However, Kellie et al. found DEP-1 
fibroblasts displayed a reduced number of cells both adhered and spread compared to control 
cells (92).  This study supported its claim with reduced FAK phosphorylation compared to 
vector controls and reduced FA formation, both associated with decreased adhesion.  Both 
studies were conducted in NIH3T3 cells and therefore the difference could lie in the matrix 
that was used (collagen 1 vs fibronectin) or the extent of over-expression of DEP-1.  These 
studies enhance the receptor dephosphorylation data, demonstrating that cell adhesion and 
migration downstream of PDGF are affected by DEP-1 protein levels.   
 
DEP-1 in cancer 
In the last several years, evidence has been published linking DEP-1 with certain cancers.  
The chromosomal location of DEP-1 has been mapped to chromosome 11p11.2 on the short 
arm of chromosome 11 (134).  Previously, loss of heterozygosity or deletion of sequences in 
the short arm of human chromosome 11 had been detected in various tumors of epithelial 
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origin, including breast cancer, bladder cancer, and hepatocellular carcinoma (159-161).  
Recent studies have looked more specifically at this chromosome, investigating the gene 
responsible for DEP-1 expression, PTPRJ.  It has been found that human colon, lung, breast 
and thyroid cancers frequently have somatic missense mutations, loss of heterozygosity, or 
deletions of the PTRRJ gene (DEP-1) (162, 163).  In addition, the mouse homologue gene, 
Ptprj, is a candidate for the mouse colon cancer susceptibility locus Scc1 (163).  DEP-1 
expression has been shown to be drastically reduced in multiple cancer cell lines and human 
cancers including thyroid, breast, pancreatic and colon cancers. (139-142, 164). Therefore, 
DEP-1 has been proposed to be a tumor suppressor.  One way in which it may be acting as a 
tumor suppressor is by inhibiting cell proliferation.  Studies have re-expressed DEP-1 in 
cancer cell lines lacking endogenous DEP-1 and found that there was a profound inhibition in 
cell proliferation (139-142, 164).  In addition, endogenous DEP-1 protein levels have been 
reduced with shRNA constructs resulting in enhanced proliferation (164), supporting a 
inhibitory role for DEP-1 in regulation of cell growth.  In fact, injection of adenovirus 
expressing DEP-1 into mice with tumors derived from injected pancreatic cancer cells 
blocked the growth of the tumors compared to untreated or control adenovirus treatment 
(142).  Restoring DEP-1 expression could be a tool for gene therapy in human (pancreatic) 
cancers. 
 A number of mutations in the DEP-1 gene, PTPRJ, have been identified and create 
coding polymorphisms often found in human cancers.  Gln276Pro, Arg326Gln, and 
Asp827Glu are mutations in the extracellular domain, specifically in the 2nd and 8th 
fibronection repeats (Fig. 1.4) (142, 163).  Sequence alignments, secondary structure 
prediction and homology modeling have predicted with high confidence that most amino acid 
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Figure 1.4.  Polymorphisms of mouse and human PTPRJ.  Schematic representation of polymorphisms that 
result in amino acid substitutions in both mouse and human.  For mice, sequences from Balb/c and STS were 
compared and positions are from Balb/c sequence.  For Human, comparisons were made from PTPRJ gene from 
colon cancer patients.  Prediction of effects of substitution for Human only:  The Arg214Cys and Arg326Gln 
substitutions are predicted to lose positive charges, Gln276Pro results in torsional stress, Pro445Leu releases 
torsional stress, and the effect of Asp873Glu has not been predicted.  The Asp1061Glu substitution is not 
expected to affect the activity of the catalytic domain, because it is conservative (involving two acidic residues) 
and affects a residue relatively distant from the active site. FNIII is fibronectin type 3 domain (striped), the 
transmembrane domain is gray and the catalytic domain is the spotted oval.  Modified from  Ruivemkamp 2002 
(163). 
 
FNIII 1 2 4 5 6 7 83
Mouse 
Human 
Leu211P
Val217Al Ala533T
Pro622S
Asp1061
Arg214C
Gln276P
Arg326G
Pro445L Asp873G
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 substitution in the extracellular domain of PTPRJ and Ptprj (the mouse homologue) occur in 
exposed regions available for interactions with ligands and other proteins and could affect the 
signaling process (163).  For example, the Gln276Pro mutation results in torsional stress and 
loss of available hydrogen bond-forming group, eventually leading to conformational 
changes in other residues in the structural “neighborhood” and potentially altering the general 
properties for interaction with extracellular ligands (163).  The Gln276Pro polymorphism 
also seems to play a critical role in susceptibility to certain human neoplasias (162).  In fact, 
PTPRJ genotypes homozygous for Gln276Pro and Arg326Gln polymorphism and the 
Asp827Glu allele were more frequent in thyroid carcinoma patients than in healthy 
individuals, suggesting PTPRJ is a  low-penetrance tumor susceptibility gene in human 
thyroid carcinogenesis (162).  These mutations in the extracellular domain may affect the 
affinity for putative ligands, responding to stimuli differently and affecting downstream  
signaling pathways.  It is also possible that these mutations may effect dimerization of DEP-1 
in cis and alter signaling in this way as well.  Functional assays with different allelic forms of 
PTPRJ will be required to further test the role of these polymorphisms.  
 
DEP-1 in hematopoietic cells 
An area of study that will not be covered in any detail in this thesis, but needs to be 
mentioned, is the role of DEP-1 in hematopoietic cells.  DEP-1, or CD148, is widely 
expressed on the membranes of human hematopoietic cells and its expression is quite 
variable between cell lineages (165-167).   Flow cytometric studies have demonstrated 
especially strong expression of CD148 on granulocytes, monocytes/macrophage, and mature  
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thymocytes (165, 166).  Weaker expression was found on peripheral blood lymphocytes, T 
cells, B cells, platelets, natural killer cells, and dendritic cells (165, 167), and poor expression 
was on transformed lymphoid T- and B- cell lines (165).   Upregulation of CD148 occurred 
on T cells following activation (165, 166, 168, 169).  Experiments in T cells have 
demonstrated a role for CD148 in the negative regulation of TCR signaling.  Increased 
expression of CD148 reduced the activation of the TCR-induced transcription factor NFAT 
(nuclear factor of activated T cells) (169-171).  In addition, CD148 can also act as a negative 
regulator by causing specific dephosphorylation of LAT (linker for activation of T-cell) and 
phospholipase Cγ1 (170).  Unlike T cells, CD148 expression levels did not change 
substantially following stimulation and activation of B cells (167), suggesting that CD148 is 
not regulating activity of B cells in a similar manner as T cells. 
Cross linking of CD148 can induce increased [Ca2+] and tyrosine phosphorylation of 
several proteins in human T cells including phospholipase Cγ1 (165).   The increased 
phosphotyrosine of intracellular proteins suggests that CD148 might regulate a protein 
tyrosine kinase whose activity is dependent on its phosphorylation status.  The inhibitory 
tyrosine residuce of src has been shown to be a substrate of DEP-1 in malignant thyroid cells 
(172) and in B cells (173) and therefore could also be a substrate in T cells and other 
leukoctyes.  The data above demonstrate that CD148 is involved in signal transduction in T 
cells and B cells, however, the significance of its action in immune response is still being 
evaluated.  It is proposed that CD148 expression could be a marker for immune activation 
but further studies will need to be conducted to fully understand its role in hematopoietic 
cells.   
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Tight Junctions 
 
Protein components of Tight Junctions 
Tight junctions are the most apical of the junctions formed by epithelia and provide a 
regulated barrier to paracellular transport of ions, solutes, water as well as cells.  They 
function as a fence, preventing the mixing of membrane proteins between the apical and 
basolateral membranes.  Tight junctions consist of 4 transmembrane proteins and several 
cytoplasmic proteins which anchor the transmembrane proteins to the actin cytoskeleton (Fig 
1.5).  Selected protein-protein interactions are depicted in Table 4.  In the transmembrane 
group there are the junctional adhesion molecules (JAMs), occludin, tricellulin, and claudins 
(174-176).  My work has focused on occludin, therefore I will not go into great detail about 
the other transmembrane proteins but will instead briefly introduce them.  Several review 
articles cover them in more depth (177-181).  The JAMs have 3 family members, A, B, and 
C.  They localize to TJ and engage in both homophilic and heterophilic adhesions, however 
do not induce the formation of TJ strands in cells lacking TJ (182).  Tricellulin is very similar 
in structure to occludin, but is only located at tricellular junctions and strengthens the barrier 
function of epithelial cell sheets (176).  The claudin family consists of 24 members with each 
exhibiting distinct expression patterns in both tissue- and cell- specific manners (reviews see 
(175, 183, 184).  Also similar in structure to occludin but not in sequence (185), claudins are 
capable of forming TJ strands when expressed in L cells, fibroblasts normally lacking TJs 
(186).  Claudins are believed to be the main TJ component driving the overall structure of TJ 
and the variety in strength, size, and ion specificity of tight junctional barriers in different  
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Figure 1.5. Schematic representation of the basic components of tight junctions.   Claudins and 
occludin/tricellulin span the membrane four times and have N- and C-terminal cytoplasmic domains.  
Tricellulin is only localized at tricellular junctions.  Junctional adhesion molecules (JAMs) are IgG-like domain 
containing proteins which can form homophilic or heterophilic interactions at junctions.  ZO-1 or ZO-2 is 
important for clustering of claudins and occludin, resulting in the formation of tight junctional strands. The role 
of the other scaffolding proteins (ZO-3/MAGI/MUP1) is less clear. The ZOs and cingulin can provide a direct 
link to the actin cytoskeleton.  Modified from (178).   
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Table 4.  Tight Junction proteins interact with several other TJ proteins 
TJ PROTEINS OTHER TJ BINDING 
PARTNERS 
Occludin ZO-1,-2,-3, cingulin 
Claudins ZO-1, -2, -3, MUPP1 
ZO-1 Occludin, claudins, ZO-2, ZO-3, cingulin, 
Ga12, F-actin 
ZO-2 Claudins, ZO-1, cingulin, F-actin 
ZO-3 Claudins, ZO-1, F-actin 
Modified from Matter et al. Curr Opin Cell Biol (192) 
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epithelia and endothelia is largely due to the type of claudin(s) found at specific tight 
junctions (175, 187).  
Occludin spans the membrane four times creating two extracellular loops with both 
an N- and C-terminal cytoplasmic tail and was the first transmembrane component of the TJ 
to be identified (188).  Early studies of both full length and mutant occludin in epithelial cells 
(MDCK) or Xenopus initially suggested a role for occludin in the barrier and fence function 
of TJs (189, 190).  Truncation and overexpression studies have shown that the N-terminal 
domains (intracellular N-terminal tail as well as 2 extracellular loops) are sufficient for 
localization of occludin to the the TJ when endogenous occludin is already present (189-
191), and for the maintenance of barrier properties of epithelia (193).   The extracellular 
domains interact in a homophilic manner and form adhesive contacts with proteins on 
adjacent cells (186).   Transfection of occludin into fibroblasts lacking TJs was able to induce 
Ca2+-independent adhesions.  Addition of synthetic peptides or antibodies corresponding to 
the extracellular domains of occludin disrupted adhesions, resulting in loss of occludin at the 
membrane and perturbing the barrier function of epithelial monolayers (194, 195).  
Therefore, interaction of the extracellular domains of occludin may be a method by which 
occludin can form an intercellular seal. 
There is also data supporting the importance of the C-terminal tail in mediating 
occludin localization at TJs.  The C-terminal tail can be divided into two distinct subdomains.  
The subdomain comprising the 150 amino acids proximal to the membrane is not highly 
charged, and is less conserved across species compared to other domains of occludin (196).  
In addition, it is not known to interact with other proteins. However, the domain 
encompassing the last 150 amino acids (ZO-binding domain) is highly charged, relatively 
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conserved across species, and binds directly to F-actin, cingulin, ZO-1, ZO-2 and ZO-3 (197-
202).  Loss of this ZO-binding domain prevents occludin localization to TJs in a bovine 
kidney cell line (198) suggesting its importance in targeting to TJs.  A connexin-occludin 
chimera containing the ZO-binding domain and not the membrane proximal domain of 
occludin was able to localize at TJs when ZO-1 is present in cells (203).  Combined these 
studies suggest the importance of this domain and for the role of cytoplasmic protein binding 
(ZO family in particular) in localizing occludin at TJs.  Although there is evidence to suggest 
that occludin is important for TJ barrier and fence function, occludin knockout mice still had 
epithelia with TJ strands and intact barrier function (204).  The mice do have mild 
phenotypes including growth retardation, male sterility and gastritis suggesting some level of 
barrier impairment (204).  Perhaps occludin is more of a regulatory player in the TJ and not 
essential to its formation.  The exact physiological function of occludin remains unclear.     
The transmembrane proteins of the TJ do not directly interact with one another; 
therefore, there are a number of cytoplasmic proteins that link the transmembrane proteins to 
each other and to the actin cytoskeleton.  These include the ZO family of proteins, cingulin 
and MUPP1/MAGI proteins (Fig. 1.5).  I will not go into great detail on cingulin and 
MUPP1/MAGI, however it is noteworthy that they are localized at the TJ cytoplasmic plaque 
and are scaffolding proteins, linking one or more transmembrane proteins with the actin 
cytoskeleton (174).  There are 3 ZO proteins, ZO-1, ZO-2, and ZO-3.  They are members of 
the MAGUK family (membrane-associated guanylate kinase-like homologs).  This family is 
characterized by N-terminal PDZ domains, a SH3, a GUK domain, an actin binding region, 
and a C-terminal proline rich region (205).  ZO-1 interacts with JAMs, forms homo- or 
heterodimers with ZO-2 and ZO-3 (201), and also directly interacts with claudins via binding 
 42
of the PDZ domains to the C-terminal tail (200). ZO-1 localization to TJ requires the actin-
binding domain (206) as well as the SH3-U5-GUK-U6 region (207).  Point mutants in the 
SH3 domain of ZO-1 have showed that the SH3 domain is important in regulating TJ 
assembly of epithelial cells (208).  ZO-1 and ZO-2 are also necessary for clustering claudins, 
TJ strand formation and barrier function (209).    
 
Tyrosine phosphorylation of Tight Junctions 
As mentioned previously in this chapter, increased tyrosine phosphorylation of AJ 
proteins decreases junctional integrity and decreases the barrier properties of epithelial and 
endothelial cells (69-71).  Components of the TJ are also regulated by tyrosine 
phosphorylation, including claudins, afadin, occludin, and ZO-1 (210, 211, Lohmann, 2004 
#560, 212,Van Itallie, 1995 #500).  I will discuss phosphorylation with regards to occludin 
and ZO-1. 
PTP inhibitor studies have demonstrated that phosphorylation of ZO-1 and occludin 
and reduced transepithelial electrical resistance (TER) of the monolayer were associated with 
reduced PTP activity (212, 213).  Oxidative stress and HGF treatment have also been shown 
to compromise barrier integrity and increase phosphorylation of both ZO-1 and occludin, 
which decreases their association with each other as shown by co-immunprecpitation and 
GST pulldown studies (214-216).  HGF treatment also prevents ZO-1 from targeting to the 
tight junction (215).  In addition, c-Src was found to bind to occludin and phosphorylate it.  
In vitro binding assays showed that when GST-c-terminal occludin was phosphorylated by c-
Src, significantly less ZO-1, ZO-2, and ZO-3 bound occludin compared to the non-
phosphorylated c-terminal occludin(217).  Strengthening of the junctions with cyclic-strain 
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produced opposite effects, with reduced permeability and occludin phosphorylation as well 
as increased occludin and ZO-1 localization to cell junctions (218).  These studies suggest 
that increased tyrosine phosphorylation at TJs is associated with junctional disassembly and 
disruption of barrier function.  They also support reports suggesting that tyrosine 
phosphorylated TJ proteins are often found in the soluble pool and non-phosphorylated forms 
are believed to be associated with the insoluble pool of proteins (219).  There are a few 
conflicting reports dealing with phosphorylation of the TJ.  Investigations have demonstrated 
that increases in phosphorylation can be associated with TJ assembly following ATP or Ca2+ 
repletion (219, 220).  In the case of the calcium repletion study, removing the calcium 
decreased occludin tyrosine phosphorylation within 2 minutes and this correlated with a 
reduction in TER.  Upon adding back calcium, tyrosine phosphorylation of occludin 
increased in parallel with an increase in TER, indicating  occludin tyrosine phosphorylation 
is linked to TJ formation (220).  These differences may have to do with different cell types 
used or the possibility that different stimuli may phosphorylate different residues. 
 
Conclusions 
PTPs play critical roles in cell-matrix adhesion dynamics as well as a central role 
regulating tyrosine phosphorylation in cell-cell adhesions.  With respect to RPTPs, the 
interactions of their extracellular domains command considerable interest due to their 
similarity with cell adhesion molecules.  Identifying their ligands is a high priority, as is 
determining whether these interactions regulate PTP activity.  The large number of PTPs 
complexing with, and acting on, cadherins and their associated proteins is striking.  Inhibiting 
PTP activity and elevating tyrosine phosphorylation at AJs and TJs promotes junctional 
 44
disassembly and affects TJ permeability.  Together these observations demonstrate the 
importance of maintaining low tyrosine phosphorylation of junctional components in order to 
maintain normal epithelial and endothelial barrier functions.  An exciting corollary of this is 
that agents that increase permeability or cells that need to cross these junctions, such as 
leukocytes or tumor cells, may modulate cell junctions by manipulating PTPs.   Exploring 
this possibility is one of the challenges facing this field. 
The effect of tyrosine phosphorylation on TJ proteins remains unclear.  Perhaps 
phosphorylation can be involved with both assembly and disassembly, depending on 
different tyrosine residues in relevant proteins.  This has been shown for focal adhesions, 
with phosphorylation of FAK leading to new binding sites for SH2 domain-containing 
proteins.  When phosphorylated, Tyr 397 interacts with the SH2 domain of Src leading to 
increased phosphorylation and the disassembly of focal adhesions.  The possibility also exists 
that tyrosine phosphorylation may affect junction permeability in a distinct way compared to 
its role in regulating assembly and disassembly of junctions.  Unfortunately, not much is 
known about this.  Mapping the phosphorylation sites and correlating changes in the 
phosphorylation states of the substrates with regards to assembly, disassembly, and altered 
permeability will eventually lead to a better understanding of what tyrosine phosphorylation 
is regulating, however this is beyond the scope of this thesis.  The next several chapters detail 
the finding that tight junction proteins and focal adhesion proteins are substrates for the 
RPTP DEP-1.  Characterizations of their interactions and consequences of their binding are 
discussed.    
 
Chapter 2: 
DEP-1 regulates phosphorylation of tight junction proteins and enhances barrier 
function of epithelial cells
 
Summary 
Cell-cell adhesion is a dynamic process that can activate several signaling pathways.  These 
signaling pathways can be regulated through reversible tyrosine phosphorylation events.  The 
level of tyrosine phosphorylation of junctional proteins reflects the balance between protein 
tyrosine kinase and protein tyrosine phosphatase activity.  The receptor tyrosine phosphatase 
DEP-1 (CD148/PTP-η) has been implicated in cell growth and differentiation as well as in 
regulating phosphorylation of junctional proteins.  The effect of tyrosine phosphorylation on 
the integrity of cell-cell junctions is still under investigation.   In this study, we used a 
catalytically dead substrate-trapping mutant of DEP-1 to identify potential substrates at cell-
cell junctions.  We have shown that in epithelial cells the trapping mutant of DEP-1 interacts 
with the tight junction proteins occludin and ZO-1 in a tyrosine phosphorylation-dependent 
manner.   In contrast, PTP-PEST, Shp2, and PTPµ did not interact with these proteins, 
suggesting that the interaction of DEP-1 with occludin and ZO-1 is specific.  In addition, 
occludin and ZO-1 were dephosphorylated by DEP-1 but not these other phosphatases in 
vitro.  Over-expression of DEP-1 increased transepithelial electrical resistance in confluent 
epithelial monolayers and also reduced paracellular flux of FITC-dextran following a 
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calcium switch.  These data suggest that DEP-1 can modify the phosphorylation state of tight 
junction proteins and play a role in regulating permeability and junction formation. 
 
Introduction 
 Tight junctions are the most apical of junctions formed by epithelia and provide a 
regulated barrier to paracellular transport of ions, solutes, macromolecules, and even other 
cells.  In addition, tight junctions act as a “fence” within the plane of the membrane, dividing 
the apical and basolateral domains of polarized epithelial cells.  These junctions play an 
important role in the regulation of multiple cellular processes including cell differentiation, 
proliferation and polarity (see reviews (192, 221)).  Functional tight junctions are 
characterized by the presence of membrane spanning proteins (claudins, occludin, and 
JAMs,) as well as cytoplasmic proteins (AF-6 and ZO-1,2,3).  Occludin spans the membrane 
four times and was the first transmembrane component of the tight junction to be identified 
(188).  It has two extracellular regions, an intracellular loop, as well as both an N and C-
terminal cytoplasmic tail (188).  The C-terminal tail of occludin binds directly to the ZO 
family of proteins, which link the protein complex to the actin cytoskeleton (197-199, 201, 
203).  The long C-terminal domain is rich in serine, threonine, and tyrosine residues, which 
can be phosphorylated by various kinases (174).  Tyrosine phosphorylation of occludin is 
associated with a decrease in transepithelial electrical resistance (TER) (212, 222) and loss of 
protein localization at the tight junction (223).    Increases in tyrosine phosphorylation of 
occludin and ZO-1 result in the dissociation of the occludin-ZO-1 complex and reduces these 
proteins localization at the tight junction (214, 217).  These data suggest that the 
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phosphorylation state of tight junction proteins can affect the integrity of the tight junction 
complex and therefore the integrity of the tight junction itself.   
Similarly, the other major junction of epithelia, the adherens junction (AJ), is 
regulated by tyrosine phosphorylation.  Increased tyrosine phosphorylation of the AJ 
decreases the stability of the cadherin-catenin complex, disrupting the association with the 
cytoskeleton and reducing junctional integrity (70, 73, 74).  Maintenance of junctional 
integrity is regulated in part by reversible tyrosine phosphorylation that results from a 
competing balance of protein tyrosine kinase (PTK) and protein tyrosine phosphatase (PTP) 
activity.  Several PTPs have been localized to AJs and shown to bind components of the 
cadherin-catenin complex.  The PTPs in AJs include receptor-PTPs (PTPµ, DEP-1, and VE-
PTP), as well as cytosolic PTPs (PTP1B and Shp-2) (78-83).  The high concentration of 
PTPs, both cytosolic and transmembrane, at cell-cell junctions indicates the importance of 
maintaining low levels of tyrosine phosphorylation at these sites, except when the junctions 
need to be remodeled or disassembled. 
DEP-1 (density enhanced phosphatase-1) is a receptor PTP that was first cloned out 
of a human cDNA library and whose expression was elevated with increasing cell density 
(89).  Also known as PTP-η, PTPRJ, and CD148, DEP-1 is comprised of an extracellular 
domain of eight fibronectin type III repeats, a transmembrane domain, and a single 
cytoplasmic catalytic domain.  The protein is ubiquitously expressed (143), suggesting it’s 
involvement in a large number of diverse signaling pathways.  DEP-1 is involved in 
regulating the differentiation of epithelial cells (139, 141, 224, 225), as well as controlling 
cell growth and adhesion (139, 141).  In addition, DEP-1 is able to attenuate the cellular 
response to growth factors through the preferential dephosphorylation of several growth 
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factor receptors,  suggesting that DEP-1 can selectively dephosphorylate certain residues to 
more finely control signaling (92, 149, 152, 153, 226). 
In addition to its role in proliferation and differentiation, DEP-1 can also localize to 
areas of cell-cell adhesion in endothelial and epithelial cells, overlapping with the AJ marker 
VE-cadherin in endothelia (90).  Direct interaction with p120 catenin as well as other 
members of the catenin family also supports the idea that DEP-1 plays a role in regulating AJ 
protein phosphorylation (80, 149).  In the current study, we investigated whether tight 
junction proteins are also substrates of DEP-1.  We now demonstrate that the substrate-
trapping mutant of DEP-1 interacts with the tight junction proteins occludin and ZO-1.  The 
association of DEP-1 with occludin and ZO-1 is specific to DEP-1 and not other 
phosphatases tested.  The binding to the trapping mutant combined with DEP-1’s ability to 
dephosphorylate occludin and ZO-1 in vitro indicates that these tight junction proteins are 
direct substrates of DEP-1.  Furthermore, increased expression of DEP-1 enhances barrier 
function as junctions reform following a calcium switch.  These results imply a role for DEP-
1 in regulating the phosphorylation state of tight junction proteins and in influencing junction 
permeability. 
 
Results 
Identification of DEP-1 substrates at the tight junction.   
To explore the function of DEP-1 at cell junctions, we sought to identify potential 
substrates of DEP-1 at the tight junction.  To accomplish this we used a substrate trapping 
mutant of DEP-1 in which the conserved aspartic acid in the WPD loop of the catalytic 
domain is mutated to an alanine (D1205A), which traps the substrate within the 
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phosphatase’s catalytic domain (8).  Cytoplasmic domains of DEP-1 wildtype (DEP-1 WT) 
and the substrate-trapping mutant (DEP-1 D/A) were expressed as GST fusion proteins and 
used in pulldown assays to identify potential physiological substrates of DEP-1.  MCF10A 
cells were treated with pervanadate to generate a pool of tyrosine phosphorylated proteins.  
As seen in Fig. 2.1A, only the substrate trapping mutant (DEP-1 D/A) was able to bind to 
phosphorylated proteins and DEP-1 D/A only bound to a subset of the phosphorylated 
proteins found in the lysate.  Interestingly, we noticed a band at approx 64-kDa that is able to 
bind DEP D/A without the addition of pervanadate.  It is possible that this protein is the 
64kDa serine/threonine kinase found constitutively associated with DEP-1 (227).   
DEP-1 is known to localize and interact with proteins located at adherens junctions 
(80, 149).  We wanted to examine whether DEP-1 can also bind to and dephosphorylate 
neighboring tight junction proteins.  To identify potential substrates, we again performed the 
GST-DEP-1 pulldown assay and probed with antibodies to known junctional proteins.  The 
tight junction proteins occludin and ZO-1 were able to bind to DEP-1 D/A in a 
phosphorylation-dependent manner (Fig. 2.1B).   The PTK src and p120 catenin, substrates 
of DEP-1 (172,Holsinger, 2002 #175), were also able to bind to DEP-1 D/A (Fig 2.1B). 
However, no interaction was detected between DEP-1 and junctional proteins E-cadherin and 
AF-6, or the cytoskeletal protein moesin (Fig. 2.1B).  We can detect an interaction between 
occludin and DEP-1 D/A with as little as 5 µg of the fusion protein and it increases in a dose-
dependent manner (Fig. 2.1C).  However, it requires 20 µg of DEP-1 D/A to detect ZO-1 
interaction (Fig. 2.1C). 
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Figure 2.1.  The substrate-trapping mutant of DEP-1 binds tight junction proteins in a tyrosine phosphorylation-
dependent manner.  MCF10A cells were either left untreated (-) or were treated (+) with 100 µM pervanadate 
for 10 mins prior to lysis.  GST alone, GST-DEP-1 WT or GST-DEP-1 D/A fusion proteins were incubated 
with cell lysates and protein complexes were analyzed by SDS-PAGE and immunoblotting with A. 
phosphotyrosine antibody (PY-20) or B. antibodies to ZO-1, occludin, src, E-cadherin, AF-6, moesin and p120 
ctn.  C. MCF10A cells were treated as described above.  Lysates were incubated with the indicated amounts of 
GST proteins and protein complexes were analyzed by SDS-PAGE and immunoblotting with antibodies to ZO-
1 and occludin. D. Effects of orthovanadate on the interaction between occludin and DEP-1 D/A.  MCF10A 
cells were treated with pervanadate as described above.  Cells were lysed with (+) or without (-) 2 mM sodium 
orthovanadate.  GST-DEP-1 fusion proteins were preincubated with (+) or without (-) 2 mM sodium 
orthovanadate and added to the lysates.  Protein complexes were analyzed by SDS-PAGE and immunoblotting 
with an occludin antibody.  The membrane was stained with Coomassie blue to confirm that equal amounts of 
GST-DEP-1 proteins were used. 
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To determine if occludin directly binds to the catalytic site of DEP-1, the GST-DEP-1 
proteins were pre-incubated with orthovanadate and tested for their ability to bind occludin.  
Orthovanadate is a competitive inhibitor that blocks the active site of DEP-1 and prevents 
substrate binding as well as enzymatic activity (228).  In the presence of orthovanadate, the 
interaction between occludin and DEP-1 D/A was inhibited (Fig. 2.1D), indicating that 
occludin binds the active site of DEP-1’s catalytic domain.  These results suggest that DEP-1 
specifically interacts with a small subset of junctional proteins that includes ZO-1 and 
occludin. 
PDZ binding tail not responsible for DEP-1 interaction with ZO-1 
The C-terminus of DEP-1 contains a type II PDZ binding tail with the last four amino 
acids being GYIA.  Previously it has been shown that the four amino acid tail can bind to the 
PDZ domains of PDZ domain-containing proteins such as syntenin (229).  ZO-1 contains 3 
PDZ domains and we wanted to test whether the interaction between DEP-1 and ZO-1 or 
even DEP-1 and occludin were due to interactions with the PDZ binding tail.  A truncation 
mutant of GST-DEP-1 D/A lacking the last four amino acids of DEP-1 (D/A Δ4) was used in 
a pulldown assay along with GST-DEP-1 D/A.  The interactions between DEP-1 and ZO-1 
or occludin were not affected by the loss of the last 4 amino acids of DEP-1 (Fig 2.2A and 
2.2B).  In addition, the binding of another known substrate, Src, was also not affected by loss 
of the last four amino acids (Fig 2.2B).  This suggests that occludin and most importantly 
ZO-1 are not binding via interactions with the C-terminal tail of DEP-1 and are likely 
binding to the catalytic domain of the PTP. 
DEP-1 dephosphorylates occludin and ZO-1.   
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Having shown that occludin and ZO-1 can bind to DEP-1, we wanted to further test 
whether they are in fact direct substrates of the phosphatase.  First, MCF10A cells were 
treated with pervanadate to induce phosphorylation of occludin and ZO-1, and then lysates 
were incubated with GST, GST-DEP-1 WT, or GST-DEP-1 D/A.  Occludin or ZO-1 was 
immunoprecipitated from the lysates and phosphotyrosine levels were revealed by blotting 
with an anti-phosphotyrosine antibody.  As shown in Fig. 2.3A, wildtype DEP-1 
dephosphorylated both occludin and ZO-1, whereas GST and DEP-1 D/A did not; these 
results confirm that occludin and ZO-1 are direct substrates of DEP-1 in vitro.  Note the 
extensive band shift of immunoprecipitated occludin incubated with DEP-1 WT is consistent 
with dephosphorylation of occludin by the PTP.  Next, we asked whether DEP-1 can 
dephosphorylate occludin when both are expressed together in cells.  Full length DEP-1 WT 
or DEP-1 D/A were co-expressed with occludin in HEK 293ft cells, occludin was 
immunoprecipitated and phosphotyrosine levels were analyzed.  In cells over expressing 
DEP-1 WT, phosphorylation of occludin was dramatically reduced compared to cells 
expressing empty vector or DEP-1 D/A (Fig. 2.3B).  These combined experiments suggest 
that both ZO-1 and occludin are substrates of DEP-1 and that DEP-1 catalytic activity is 
required for the dephosphorylation of occludin in vivo. 
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Figure 2.2.  The PDZ tail of DEP-1 is not responsible for the interactions with substrates.  A truncation mutant 
of DEP-1 missing the last four amino acids of the C-terminal tail was expressed as a GST fusion protein (GST-
DEP-1 D/A Δ4) and tested for interaction with DEP-1 substrates.  MCF10A cells were either left untreated (-) 
or were treated (+) with 100 µM pervanadate for 10 mins prior to lysis.  Lysates were incubated with GST, 
GST-DEP-1 D/A (D/A), or GST-DEP-1 D/A Δ4 (D/A Δ4) and protein complexes were resolved with SDS-
PAGE and immunoblotting with A. ZO-1 antibody or B. Occludin and Src antibodies.  The smear in the GST 
lanes of (A) appear to be the non-specific binding of proteins and was found in the entire length of the lane.  
The GST control was not shown in (B) but previous experiments have never shown occludin binding to GST 
.    
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Figure 2.3.  DEP-1 dephosphorylates occludin and ZO-1.  A. In vitro dephosphorylation assay.  MCF10A cells 
were treated with 100 µM pervanadate for 10 mins prior to lysis.  Lysates were incubated with glutathione 
sepharose bound GST or GST-DEP-1 fusion proteins and then the fusion proteins were removed by 
centrifugation.  Occludin and ZO-1 were immunoprecipitated from the remaining lysates.  Immunocomplexes 
were analyzed by SDS-PAGE and immunblotted with PY-20 antibody or occludin/ZO-1 antibodies.  B. In vivo 
dephosphorylation assay.  HEK 293ft cells were transfected with occludin and empty pMT2 vector or 
pMT2.DEP-1 WT or pMT2.DEP-1 D/A.  Cells were treated with pervanadate (as in A), lysed and 
immunoprecipitated with an anti-occludin antibody.  Samples were analyzed by SDS-PAGE and 
immunoblotted with anti-phosphotyrosine antibody or anti-occludin antibody. 
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Occludin and ZO-1 interaction is specific to DEP-1.   
We wanted to determine if the interaction of DEP-1 with occludin and ZO-1 was 
specific or if these proteins were substrates of additional PTPs.  Lysates of untreated or 
pervanadate treated MCF10A cells were incubated with GST fusion proteins of the substrate 
trapping mutants of DEP-1 (GST-DEP-1 D/A), PTP-PEST (GST-PTP-PEST D/A), and other 
junctional PTPs including Shp2 (GST-Shp2 C/S), and PTPµ (GST-PTPµ D/A).  DEP-1 D/A 
was the only PTP of those tested that was able to interact with ZO-1 and occludin, and it did 
so in a tyrosine phosphorylation-dependent manner (Fig. 2.4A, 2.4B).  To confirm that the 
substrate-trapping mutants were functional, pulldowns were blotted with an anti-
phosphotyrosine antibody, and all were found to bind tyrosine-phosphorylated proteins (Fig. 
2.5).  In addition, membranes were stained with coomassie blue to confirm the use of equal 
amounts of PTP fusion proteins (Fig 2.4B).  We also confirmed that other PTP’s were 
comparatively inefficient at dephosphorylating occludin and ZO-1.  MCF10A cells were 
treated with pervanadate to induce protein phosphorylation and incubated with wildtype GST 
fusion proteins of DEP-1, PTP-PEST, PTPα, and PTPµ.  Following incubation, fusion 
proteins were removed by centrifugation, and then occludin and ZO-1 were 
immunoprecipitated and phosphotyrosine levels analyzed.  As shown in Fig. 2.4C and 2.4D, 
GST-WT DEP-1 was able to completely dephosphorylate occludin and ZO-1 whereas the 
other PTPs had little effect.  Again, notice the decrease in molecular weight of the occludin 
that accompanied dephosphorylation by DEP-1 WT (Fig. 2.4C).  These results suggest that 
occludin and ZO-1 are specific substrates of DEP-1 and not other PTPs tested.   
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Figure 2.4.  Occludin and ZO-1 are specific substrates of DEP-1. A & B. Substrate-trapping mutants of different 
PTPs.  MCF10A cells were either left untreated (-) or were treated (+) with 100 µM pervanadate for 10 mins 
prior to lysis.  Lysates were were incubated with the GST-fusion proteins of the substrate trapping mutants of 
the indicated cytoplasmic and receptor PTPs.  Protein complexes were analyzed by SDS-PAGE and 
immunoblotted for A, ZO-1 and B, occludin.  Membranes were stained with coomassie blue to confirm equal 
amount of PTP fusion proteins were used.  C & D. In vitro dephosphorylation assay.  MCF10A cells were 
treated with 100 µM pervanadate for 10 mins prior to lysis.  Lysates were incubated with GST or wildtype 
GST-PTP fusion proteins bound to glutathione sepharose, the fusion proteins were removed by centrifugation 
and C, occludin or D, ZO-1 were immunoprecipitated from the lysates.  Immunocomplexes were analyzed by 
SDS-PAGE and immunblotted with a PY-20, occludin, or ZO-1 antibody. 
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Figure 2.5. Substrate trapping mutants of PTPs are able to bind tyrosine phosphorylated proteins.  MCF10A 
cells were either left untreated (-) or were treated (+) with 100 µM pervanadate for 10 mins prior to lysis.  
Lysates were incubated with GST, GST-DEP-1 D/A, GST-PTP-PEST D/A, and GST-Shp2 C/S for 1 hour and 
protein complexes were resolved with SDS-PAGE and immunoblotting with anti-phosphotyrosine antibody 
(PY20).  The two panels represent two exposure lengths.  The PTP-PEST (-) PV lane has contaminating signal 
from the DEP-1 D/A (+) PV lane adjacent to it.   
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SAP-1 can dephosphorylate occludin 
SAP-1 (stomach cancer-associated protein tyrosine phosphatase-1) is a receptor PTP 
which is structurally similar to DEP-1 with an extracellular domain of 8 fibronectin type III 
repeats, a transmembrane domain and a single intracellular catalytic domain (230).  With its 
known structural similarity to DEP-1, we were interested in determining whether the tight 
junction proteins occludin and ZO-1 are substrates of SAP-1.  We tested the catalytically 
inactive mutant of SAP-1 C/S in GST fusion pulldowns and found that occludin did not bind 
to this phosphatase compared to DEP-1 D/A (Fig. 2.6A, 2.6B).  In addition, ZO-1 was not 
able to be pulled down with SAP-1 C/S (Fig. 2.6B). 
We also examined the ability of SAP-1 to dephosphorylate occludin in an in vitro 
dephosphorylation assay.  MCF10A cells were treated with pervanadate and the lysates were 
incubated with GST, GST DEP-1 WT or GST SAP-1 WT.  Occludin was 
immunoprecipitated from the lysates and phosphotyrosine levels were determined by 
immunoblotting with a phosphotyrosine antibody.  SAP-1 was able to visibly 
dephosphorylate occludin and appears to do so even better than DEP-1 (Fig 2.6C).  Both 
PTPs have a dose dependent affect on phosphotyrosine levels.  The preliminary results 
suggest that occludin may in fact be a substrate for SAP-1.  This would not be all together 
surprising based on the similarities between the two PTPs. 
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Figure 2.6. SAP-1 cannot bind occludin and ZO-1 but can dephosphorylate occludin.  A.  MCF10A cells were 
either left untreated (-) or were treated (+) with 100 µM pervanadate for 10 mins prior to lysis.  Lysates were 
incubated with GST, GST-DEP-1 D/A or GST-SAP-1 C/S.  Protein complexes were resolved with SDS-PAGE 
and immunoblotting with an occludin antibody.  The membrane was also stained with coomassie blue to ensure 
equal amounts of fusion proteins were used.  B.  Lysates were prepared as in A.  and incubated with GST, GST-
SAP-1 WT and GST-SAP-1 C/S.  Membranes were probed with ZO-1 and occludin antibodies and neither were 
found to interact with the SAP-1 proteins.  C.  In vitro dephosphorylation assay.  MCF10A cells were treated 
with 100 µM pervanadate for 10 mins prior to lysis.  Lysates were incubated with GST or wildtype GST-DEP-1 
and GST-SAP-1 bound to glutathione sepharose.  The fusion proteins were removed by centrifugation and 
occludin was immunoprecipitated from the lysates.  Immunocomplexes were analyzed by SDS-PAGE and 
immunblotted with a PY-20 or occludin antibody. 
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DEP-1 binds and dephosphorylates Src-induced phospho-occludin 
There are 43 tyrosines in occludin, 23 of which are located in either the intracellular 
N- or C-terminus.  In the previous experiments we used pervanadate to induce tyrosine 
phosphorylation of junctional proteins.  Pervanadate is an irreversible PTP-inhibitor that is 
102-103 times more potent than vanadate alone (Kadota, Posner 1987; Fatutus and posner 
1989).  This allows us to increase pools of tyrosine phosphorylated proteins, however, it is 
difficult to determine which kinase is acting on our substrates or which residues are 
phosphorylated.  The identification of kinase(s) acting on the tight junction proteins as well 
as the tyrosine residues that DEP-1 is binding would help to clarify how tyrosine 
phosphorylation is regulating tight junction function.  One potential kinase is Src kinase.  Src 
localizes to tight junctions (231), binds ZO-1 (232), and can phosphorylate occludin in vitro 
leading to disruption of TJs (217).  There are several Src consensus sites in the N-and C-
terminal tails of occludin and DEP-1 may be able to bind to one of these sites.  First, we 
examined whether constitutively active Src (Y527F) was able to phosphorylate occludin in 
transfected cells.  HEK 293ft cells were co-tranfected with full length occludin and either 
empty vector or pCMV-SrcY527F.  Cells were lysed in hot SDS sample buffer, occludin was 
immunoprecipitated, and phosphotyrosine levels were analyzed.  Expression of constitutively 
active Src was able to phosphorylate occludin (Fig. 2.7A), supporting data by Kale et al. 
(217).  Next, we determined whether the Src induced phospho-occludin was able to bind to 
the substrate trapping mutant of DEP-1.  Again, HEK 293ft cells were transfected with 
occludin and either empty vector or SrcY527F.  GST-DEP-1 pulldown assays were 
performed with the lysates from the transfected cells and the membranes were probed for 
occludin.  We found that Src-phosphorylated occludin interacted with the substrate trapping 
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mutant of DEP-1 (Fig. 2.7B).  Knowing that Src can phosphorylate occludin and these 
phosphorylation sites interact with the substrate trapping mutant of DEP-1, we tested whether 
wildtype DEP-1 can dephosphorylate Src-induced phospho-occludin.  We expressed 
wildtype or the catalytically inactive substrate trapping mutant of DEP-1 with occludin and 
SrcY527F in HEK 293 cells, immunoprecipitated occludin and analyzed phosphotyrosine 
levels.  The addition of DEP-1 WT reduced the phosphotyrosine levels of occludin, 
suggesting that DEP-1 was able to dephosphoorylate Src phosphorylation sites (Fig. 2.7A).  
It is interesting to note that HEK 293ft cells have endogenous DEP-1 and when transfected 
with constitutively active Src, endogenous DEP-1 levels increase (Fig. 2.7A).   
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Figure 2.7.  Src phosphorylation of occludin and induced interaction with DEP-1.  A.  HEK 293ft cells were 
transfected with occludin, occludin and constitutively active Src (SrcY527F), or occludin, SrcY527F, and DEP-
1 WT.  Cells were lysed in hot 2X SDS gel sample buffer and samples were then diluted 20-fold with phospho-
IP buffer to a final SDS concentration of 0.1%.  Occludin was immunoprecipitated, IPs resolved by SDS-PAGE 
and membranes were probed with PY-20 or occludin.  In addition, lysates were blotted for src and DEP-1 
expression.  B.  HEK 293ft cells were transfected with SrcY527F and occludin and lysates were used in a 
pulldown assay with GST, GST-DEP-1 WT and GST-DEP-1 D/A.  Lysates and pulldowns were resolved by 
SDS-PAGE and immunoblotting for src and occludin expression as well as occludin binding to the fusion 
proteins.  The membrane was subsequently stained with coomassie blue to ensure equal amounts of GST fusion 
proteins were used in each pulldown.   
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DEP-1 and occludin co-localize at areas of cell-cell contact.   
Previous studies have shown that DEP-1 localizes at points of cell-cell contact as well 
as along the apical plasma membrane (80, 90).  We wanted to examine to what extent DEP-1 
and occludin co-localize along cell tight junctions.  MDCK II cells were transfected with 
GFP or DEP-1 WT-GFP and were stained with anti-occludin antibodies to visualize 
endogenous occludin at tight junctions.  As shown in Figure 2.8, there was significant 
colocalization of DEP-1 and occludin at sites of cell-cell contact. 
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Figure 2.8.  DEP-1 localizes to areas of cell-cell contact.  MDCK II cells were transfected with pEGFP or 
pEGFP-DEP-1 (a,d) and stained for occludin (b,e).  Merged images show colocalization in yellow (c,f). Scale 
bar = 10 µm. 
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DEP-1 expression enhances barrier function as junction reassemble.   
We next wanted to determine whether our previously observed dephosphorylation of 
occludin and ZO-1 had functional consequences with respect to tight junction physiology.  
MDCK II cells were infected with GFP or DEP-1 WT adenovirus, plated onto transwell 
filters, and 4 days later the transepithelial electrical resistance (TER) of the stable junctions 
was measured.  In epithelial cells overexpressing DEP-1 we saw a small but significant 
increase in TER compared to the GFP control (p<0.005) (Fig. 2.9), supporting the hypothesis 
that expression of DEP-1 can decrease the permeability of the tight junction. 
To better address the ability of DEP-1 to regulate tight junction function, we looked 
at FITC-dextran flux across an epithelial monolayer during junctional reassembly following a 
calcium switch.  MDCK II cells were infected with GFP or DEP-1 WT adenovirus and plated 
on transwell filters.  After cells had adhered, growth media was replaced with low calcium (5 
µM) media overnight.  Normal calcium-containing media (1.8 mM) was then added to the 
transwells and the ability of FITC-dextran to pass across the monolayer was assessed at 0, 6, 
12, 24 and 48 hours.  The amount of FITC-dextran that crossed the monolayers was 
significantly reduced as junctions reassembled (Fig. 2.10A).  At early stages of junction 
reassembly (6 hrs), the presence of additional DEP-1 WT decreased permeability indicated 
by the further decrease of FITC-dextran flux compared to GFP control cells (Fig. 2.10A, 
2.10B.)  After 12 and 24 hours in calcium-containing media, the permeability between GFP- 
and DEP-1 expressing cells was not significantly different (Fig. 2.10A, 2.10B).  In identical 
experiments, TER was measured following the calcium switch.  Monolayers over-expressing 
DEP-1 WT have higher TER than GFP controls at early time points of junction reassembly 
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(Fig. 2.10C).  Together the TER and FITC-dextran data reveal that an increase in DEP-1 WT 
enhances the barrier function of  
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Figure 2.9.  DEP-1 enhances junctional integrity in epithelial cells.  MDCK II cells were infected with GFP 
alone or DEP-1 WT adenovirus, plated on filters (0.4µm pore) and allowed to grow into confluent monolayers.  
Transepithelial electrical resistance was taken at 4 days post plating.  Values are expressed as the mean ± SEM 
of 4 experiments performed in triplicate.  Baseline TER ranges from 45-50 ohms/cm2.  Asterisk indicates the 
value is significantly (p<0.005) different from corresponding values for control group (GFP). 
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Figure 2.10.  Expression of DEP-1 enhances barrier function as junctions reassemble.  MDCK II cells were 
infected with GFP or DEP-1 WT adenovirus and grown on filters as confluent monolayers.  Cells were 
incubated in low calcium media (5 µM) for ~16 hours to completely disrupt junctions (as measured by TER), 
and then transwell filters were switched to normal calcium media (1.8 mM).  A. At varying time points after the 
addition of calcium media, 10-kDa FITC-dextran was added to the top chamber of the transwell filter and 
allowed to cross the cell monolayer for one hour.  Values across all times were normalized to the amount of 
FITC-dextran flux that crossed the GFP control cell monolayer at 0 hrs.  The amount of FITC-dextran that 
crossed the monolayer was analyzed using a fluorometer (excited 485 nm, emission 520 nm).  The graph shows 
a representative experiment. B. To directly compare flux differences at specific time points, values were 
normalized to GFP controls at 6 hrs, 12 hrs and 24 hrs.  Data are expressed as mean ± SEM of at least 3 
experiments performed in at least duplicate.  Asterisk indicates the value is significantly (p<0.01) different from 
corresponding values for control group (GFP).  C. TER was measured over 72 hours after the calcium switch.  
Data is expressed as mean ± SEM of filters in triplicate.  This graph shows a representative experiment. 
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epithelial junctions during reassembly. Thus, the presence of DEP-1 is particularly important 
at the earliest, most dynamic stages of junctional assembly. 
 
Discussion 
Cell-cell junctions can be regulated through reversible tyrosine phosphorylation.  
Tyrosine phosphorylation of adherens junction proteins has been shown either to promote the 
dissociation of protein complexes at the junction (70, 73, 74, 77) or to promote the 
internalization and degradation of junctional proteins (76).  Whereas most work in this area 
has focused on the tyrosine kinases that act on junctional proteins, it is equally important to 
identify the PTPs and their targets within cell-cell junctions. Here we show for the first time 
that the prominent tight junction proteins, occludin and ZO-1, interact with and are 
dephosphorylated by the PTP DEP-1. Experimentally increasing the levels of DEP-1 reduced 
the permeability of epithelial monolayers and this effect was enhanced during the early 
stages of junction assembly.   
Similar to the adherens junctions, tyrosine phosphorylation has been correlated with 
the dissociation of tight junction components, promoting the detachment of ZO-1 from 
occludin (214, 215, 217, 233, 234).  This increased tyrosine phosphorylation of tight junction 
components is paralleled by increased epithelial permeability.  Because DEP-1 has 
previously been localized to regions of cell-cell contact (80, 90), we examined whether the 
phosphorylation of tight junction proteins was regulated by this PTP.  We found that the 
catalytically dead trapping mutant of DEP-1 binds to phosphorylated forms of occludin and 
ZO-1 and that catalytically active DEP-1 dephosphorylates these proteins.  Previous work 
has shown that DEP-1 interacts with and acts on the adherens junction proteins p120catenin 
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and β-catenin (80, 149), and we have confirmed these interactions (Fig. 2.1B and data not 
shown).  However, we found that DEP-1 does not bind all tyrosine phosphorylated junctional 
proteins (Fig. 2.1B).  It is striking that several PTPs are concentrated within epithelial 
junctions (235) and it is likely that there is some redundancy with respect to their targets.  
However, we were surprised to find that two junctional PTPs, PTPμ and SHP-2, did not 
significantly interact with or dephosphorylate occludin and ZO-1 (Fig. 2.4).  This result 
suggests that the different PTPs within cell-cell junctions have specific targets and that they 
may regulate distinct signaling pathways.  These pathways may either be initiated within 
junctions in response to cell-cell interactions or be triggered by a stimulus such as growth 
factors or oxidative stress to regulate junction stability, strength, and permeability.  It is 
worthy of note that we discovered that the highly homologus PTP SAP-1 is able to 
dephosphorylate occludin although no interactions with the substrate trapping mutant (SAP-1 
C/S) were found.  The C/S mutation in PTP catalytic domains does not have as high an 
affinity for substrates since the mutation is of the catalytic cysteine.  As a result, the C/S 
mutant is not as efficient at binding substrates as compared to the D/A mutant (8).  Noguchi 
et al. (236) have specifically shown that SAP-1 C/S is less efficient at binding proteins from 
pervanadate treated cells than SAP-1 D/A.  Therefore, the D/A mutant will be made in the 
GST-SAP-1 construct and this experiment will be repeated to clarify whether tight junction 
proteins may be substrates.  This may provide evidence that although different types of PTPs 
may have different substrates, PTPs within the same family type may regulate similar 
signaling pathways. 
Having found that DEP-1 dephosphorylates occludin and ZO-1, we wanted to explore 
DEP-1’s effect on tight junction function in epithelial cells.  Mature junctions are thought to 
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exist in a tyrosine dephosphorylated state, with increased tyrosine phosphorylation leading to 
increased junction disassembly, increase paracellular permeability and can induce 
reorganization of the junctional complex (212, 222).  Thus, dephosphorylation of occludin as 
well as other junctional proteins, is believed to increase the barrier function of the junction.  
Our over-expression of DEP-1 in epithelial cells increased TER (Fig. 2.9), a measure of 
increased barrier properties of the junctions, consistent with phosphorylation regulating the 
permeability of tight junctions. Although the difference was subtle (5-10% increase), it was 
reproducible and statistically significant.  We believe the small effect on TER is due to the 
fact that the cells had been confluent for several days.  At this point, the junctions have 
reduced dynamics and the level of tyrosine phosphorylation is very low (essentially 
undetectable).  Because tyrosine phosphorylation is elevated during disassembly/assembly of 
junctions, this led us to explore the effect DEP-1 had on junctional permeability as the 
junctions were assembling.  Using the established calcium switch technique (237, 238) to 
modulate cell-cell adhesion, we measured the permeability of epithelial junctions with both 
TER and FITC-dextran flux over a time course of junction reassembly.  As shown in Figure 
2.10A, as junctions reassemble after calcium addition, the permeability decreases over time.  
Importantly, when comparing the permeability of GFP-expressing versus DEP-1-expressing 
cells at 6 hrs following calcium restoration, the presence of DEP-1 significantly reduces the 
permeability of FITC-dextran flux, suggesting that these junctions reassembled more rapidly 
(Fig. 2.10B).  By 12 and 24 hours the difference in permeability between GFP- and DEP-1-
expressing cells was not statistically significant (Fig. 2.10B).  The TER data shows a slightly 
shifted trend, with the cells over-expressing DEP-1 still maintaining an increase in TER at 12 
hrs following the initiation of reassembly.  This difference may reflect the difference between 
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measuring the permeability of ions versus macromolecules in epithelial cells.  Overall, our 
results suggest a model in which DEP-1 is a receptor PTP that localizes to cell-cell junctions, 
and is able to regulate phosphorylation levels of junctional proteins (Fig. 2.11).  In this way, 
it aids in the reformation of the tight junction complex and enhances barrier function of 
epithelial junctions during Ca++-induced reassembly.  
DEP-1 was first identified as a PTP whose expression was enhanced with increasing 
cell density, suggesting its potential role in contact inhibition of growth (89).  In recent years 
much work has been done to characterize the role of DEP-1 in cell proliferation and 
differentiation.  DEP-1 can inhibit cell proliferation in a number of different cell types (140, 
150, 164) and attenuates signaling downstream of growth factors by targeting the growth 
factor receptors themselves (92, 149, 152, 153).  Studies have also found DEP-1 involved in 
cell differentiation (139, 162).  Transformation of several cell types inhibited DEP-1 
expression and reintroduction of the protein reduced growth and partially reverted the 
neoplastic phenotype (141, 142, 162).  Frequent deletions, missense mutations, and loss of 
heterozygosity of DEP-1 have been found in a number of human cancers, including colon, 
lung and breast (163).  These studies implicate the loss of DEP-1 as a factor in the 
disregulation of growth and differentiation in numerous tyrpes of cancers, and led to the 
proposal that it is a tumor suppressor.  The action of DEP-1 on both adherens and tight 
junctions suggests another means by which DEP-1 may protect cells from oncogenic 
transformation and metastasis; controlling the strength and stability of cell-cell interactions.  
Diminished interaction of a cell with its neighbors is a hallmark of cancer and particularly 
associated with tumor invasion and metastasis.  In future work, we hope to examine whether 
the relationship of DEP-1 with occludin and ZO-1 is changed in specific epithelial tumors. 
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The continued identification of junctional substrates of DEP-1 will aid in furthering our 
understanding of the role of this PTP in diseases such as cancer. 
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Figure 2.11.  Model of how DEP-1 may regulate tight junction integrity.  The transmembrane protein occludin 
binds via its C-terminal tail to the cytoplasmic ZO family of proteins.  These ZO proteins link the complex to 
the actin cytoskeleton creating a stable complex and intact junction.   Tyrosine phosphorylation events by Src or 
other PTKs can phosphorylate both occludin and ZO-1, disrupting their interactions with each other and 
reducing junction integrity.  DEP-1 is a receptor PTP which is able to dephosphorylate both occludin and ZO-1 
and may aid in reforming intact junctions.  
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Materials and Methods 
Cell Culture and Transfections-- MCF10A cells were grown in a 1:1 mixture of Dulbecco’s 
modified Eagle’s medium (DMEM) and F12/Ham medium supplemented with 5% horse 
serum, 20 ng/ml EGF, 0.01 mg/ml insulin, 500 ng/ml hydrocortisone, 100 ng/ml cholera 
toxin and antibiotics.  MDCK II and HEK 293ft cells were cultured in Dulbecco's modified 
Eagle's medium-high glucose enriched with 10% fetal bovine serum and antibiotics.  Cells 
were transfected with Lipofectamine 2000 (Invitrogen) or Fugene6 (Roche Applied Science) 
according to the manufacturer’s instructions. 
 
Constructs and Antibodies--pMT2 DEP-1 WT and pMT2 DEP-1 D/A (GenBank TM 
accession number U10886) were kindly provided by Nicholas Tonks (Cold Spring Harbor).  
pEGFP DEP-1 WT and pEGFP DEP-1 D/A were generated by sub cloning the pMT2 
contructs into pEGFP-N2 (Clontech).  DEP-1 cytoplasmic domain constructs were generated 
using the pMT2 DEP-1 wildtype or D1205A point mutant as templates.  A 5’ primer 
introduced an EcoR1 before the DEP-1 cytoplasmic sequence at nucleotide 3338 and a 
3’primer introduced a Xho1 site after the DEP-1 stop codon.  The resulting PCR fragments 
(nucleotides 3338-4362) were cloned into the EcoR1/Xho1 sites of the pGEX-4T-1 vector 
(GE Healthcare), creating wildtype and point mutant D1205A pGEX-DEP-1 constructs.  The 
GST-DEP-1 D/A Δ4 construct was generated using the same 5’ primer as above and a 3’ 
primer which inserted a stop codon after nucleotide 4350.  GST-PTP-PEST wildtype and 
substrate trapping mutant were obtained from Dr. Sarita Sastry (University of Texas 
Galveston), GST-PTP µ wildtype and substrate trapping mutant were kind gifts from Dr. 
Susann Brady-Kalnay (Case Western), and GST SAP-1 constructs were given by Takashi 
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Matozaki (Gunma University, Japan).  Full length occludin was provided by Alan Fanning 
(University of North Carolina Chapel Hill).  Constitutively active (Y527F) src was obtained 
from Daniel Flynn (West Virginia University). For adenovirus, the full length cDNA of 
DEP-1 WT was cloned into pENTR1D (Invitrogen). The entry clone was recombined with 
the pAd/CMV/V5 destination vector via LR clonase II. The ViraPower Adenviral expression 
vector (Invitrogen Life Technologies) was linearized and then transfected into 293A cells via 
Lipofectamine 2000 to generate adenovirus encoding V5-tagged DEP-1.  The virus particles 
were used to infect MDCK II cells. 
Mouse anti-occludin and rabbit anti-ZO-1 antibodies were purchased from Zymed 
Laboratories Inc.  Mouse anti-human CD148 (DEP-1) antibody was purchased from 
Biosource.  GFP monoclonal antibody was from Roche.  Monoclonal antibodies to E-
cadherin, moesin and p120ctn were purchased from BD Bioscience, anti-Src was purchased 
from Millipore, AF-6 rabbit polyclonal was from Novus Biological, and monoclonal PY-20 
was purchased from Santa Cruz Biotechnology. 
 
GST fusion proteins-- Expression of the fusion proteins in Escherichia coli were induced with 
100 μM IPTG (isopropyl-β-D-thiogalactopyranoside) for 16 hours at room temperature.  
Bacterial cells were lysed in buffer containing 50 mM Tris (pH 7.6), 150 mM NaCl, 1% 
Triton X-100, 5 mM MgCl2, 1 mM DTT, 10 μg/ml each of aprotinin and leupeptin, and 1 
mM phenylmethylsulfonyl fluoride (PMSF) and the fusion proteins were purified by 
incubation with glutathione-sepharose 4B beads (GE healthcare) at 4ºC.  Catalytic activity of 
the fusion proteins was checked by PTP activity assays using pNPP (p-nitrophenylphosphate 
(Sigma)). 
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Substrate Trapping Pulldown-- MCF10A cells were either left untreated or treated with 100 
μM pervanadate (phosphatase inhibitor) for 15 mins prior to lysis.  Cells were rinsed twice in 
phosphate-buffered saline and lysed in a modified RIPA buffer (1% Tx-100, 0.5% DOC, 
0.2% SDS, 150 mM NaCl, 20 mM Hepes ph 7.4, 2 mM EDTA, 10 μg/ml each aprotinin and 
leupeptin, and 1mM PMSF).  Insoluble material was removed by centrifugation. MCF10A 
lysates (1 mg) were incubated with 10 μg of GST proteins for 1 hour at 4ºC.  Beads were 
washed in the modified RIPA buffer, resuspended in Laemmli sample buffer and analysed by 
SDS-PAGE and western blotting on PVDF membranes (Millipore). 
To determine whether the substrates were binding DEP-1 D/A at the PTP active site, 
we tested the effect of orthovanadate on complex formation.  GST fusion proteins bound to 
glutathione sepharose were preincubated in a Hepes lysis buffer (1% Tx-100, 150 mM NaCl, 
20 mM Hepes, pH 7.5, 5 mM MgCl2,) with or without 2 mM orthovanadate.  MCF10A cells 
were treated with 100 μm pervanadate for 20 mins and also lysed in Hepes lysis buffer with 
or without 2 mM orthovanadate.  Lysates ( 500 μg – 1mg) were incubated with 2 μg of GST-
DEP-1 or GST-DEP-1 D/A for 1.5 hours at 4ºC.  Beads were washed in the Hepes Lysis 
buffer, resuspended in Laemmli sample buffer, and analysed by SDS-PAGE and western 
blotting on PVDF membranes. 
 
Dephosphorylation Assays-- MCF10A cells were treated with 100 µM pervanadate for 15 
mins and lysed in the modified RIPA buffer plus 10 μg/ml each aprotinin and leupeptin, 
1mM PMSF, and 5 mM iodoacetic acid (IAA).  After incubation of the lysates on ice for 10 
mins, DTT was added at a final concentration of 10 mM for another 10 mins on ice to 
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inactivate the IAA.  Lysates were clarified and 500 μg of total cell lysate was incubated with 
1 μg glutathione-sepharose bound GST-PTPs for 20 minutes at room temperature.  The 
phosphatases were removed by centrifugation, orthovanadate was added to the samples and 
occludin was immunoprecipitated for 2 hours at 4 ºC.  Beads were washed in the lysis buffer 
and processed for SDS PAGE.  The immune complexes were analyzed by western blotting 
using the PY-20 antibody, occludin monoclonal antibody or ZO-1 polyclonal antibody.  
Alternatively, HEK 293ft cells were transfected with pMT2 contructs for 48 hours and lysed 
directly in hot 2x SDS gel sample buffer (200mM Tris (pH 6.8), 20% glycerol, 4% SDS, 5% 
2-ME), and boiled for 10 min. Samples were then diluted 20-fold with phospho-IP buffer 
(150 mM NaCl, 20 mM Tris, pH 7.6, 1% Triton X-100, 1% sodium deoxycholate, 1 mM 
sodium orthovanadate, 10 µg/ml leupeptin, 10 µg/ml aprotinin) to a final concentration of 
0.1% SDS. One µg of occludin antibody and protein G-sepharose were added and samples 
were incubated for 4 hours at 4°C. Samples were then washed in TBS and analyzed by 
Western blot using anti-PY20 antibody. 
 
Immunofluorescence-- MDCK II cells were fixed with 3.7% formaldehyde in phosphate 
buffered saline and permeabilized in 0.5% Tx-100.  Occludin was visualized cells with anti-
occludin monoclonal antibody (Zymed) at 1:200 for 45 mins at 37ºC followed by an anti-
mouse Alexa-594 conjugated secondary antibody.  Images were recorded with a Zeiss 
LSM510 confocal microscope. 
 
Calcium Switch experiments—MDCK II cells were plated at confluent density (~4 x105 
cells/cm2) onto Transwell filters (0.4 µm pore, 12mm diameter; Corning). Growth media was 
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removed from cells 3-4 hours after plating and replaced with DMEM containing low calcium 
(5 µM) overnight (~16 hours). Disruption of cell-cell junctions was confirmed by TER 
measurements of only 2 ohms/cm2.  Junction reassembly was induced with the addition of 
calcium containing DMEM (1.8 mM CaCl2) for the indicated length of time. 
 
Permeability assays--TER: MDCK II cells were infected with pAd/CMV/GFP or 
pAd/CMV/V5-DEP-1 WT.  24 hours later, cells were plated at confluent density (~4 x105 
cells/cm2) onto Transwell filters (0.4 µm pore, 12mm diameter; Corning) and cultured for 4 
days, with media replacement daily.  TER was measured using an Endohm-12 Transwell 
chamber connected to an EVOM voltohmeter according to the manufacturer’s instructions.  
For calcium switch experiments, TER was measured at indicated time points following the 
re-addition of calcium containing media.  The resistance of the filter was subtracted from all 
readings.   
FITC-Dextran flux:  MDCK II cells were infected with DEP-1 or GFP control adenovirus 
and plated the same as for the TER measurements above.    For the calcium switch, calcium 
containing DMEM was added to the chambers for indicated length of time; 1 ml in the outer 
chamber and 250 µl in the inner chamber.  10-kDa FITC-dextran (Molecular Probes) was 
added to the top chamber in a volume of 50 µl at a final concentration of 1 mg/ml.  After 1 
hour, a sample was removed from the basolateral (bottom) compartments and read in a 
fluorometer (FluroStar) (ex 485nm, em 520 nm). 
 
Statistics—Comparison between two groups was made by the Student’s t test for unpaired 
data. 
.Chapter 3: 
Mapping the Region of Occludin Necessary for DEP-1 Interaction 
 
Summary 
In the previous chapter novel interactions were discovered between the PTP DEP-1 and 
members of the tight junction.  Specifically, we were able to characterize occludin as a 
substrate of DEP-1 in epithelial cells.  Occludin binds to the catalytic domain of DEP-1 and 
not to the PDZ tail, however it is not known which region of occludin is responsible for its 
interaction with DEP-1.  Due to the larger number of intracellular tyrosines (23) in occludin, 
this has been difficult to determine.  Using truncation mutants we attempted to map the 
region in the C-terminal tail of occludin that binds to DEP-1.  In pervanadate treated HEK 
293ft cells all C-terminal occludin mutants are able to bind the substrate trapping mutant of 
DEP-1.  This suggests that multiple sites may be important for this interaction.  Future 
experiments will focus specifically on residues in the ZO-1 binding site.   
  
Introduction 
The importance of occludin in tight junctions remains to be definitively resolved.  
Mice lacking occludin show no abnormal phenotype and their epithelia still maintained TJ 
strands and intact barrier function (204).  Nevertheless, over-expression studies of full length 
occludin have demonstrated that occludin is a functional component of the TJ (189, 239).  
The N-terminal domains of occludin have been implicated in being necessary for correct 
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localization of occludin.  Two studies have reported that occludin lacking the C-terminal 
cytoplasmic domain can localize to the TJ when endogenous occludin is present (189, 190) 
suggesting that the N-terminal domain is sufficient for localization.  In addition, expression 
of an N-terminally truncated occludin disrupted tight junction integrity, demonstrating the 
role of the N-terminal domain of occludin in maintaining epithelial barrier function (193).     
In contrast, there is also evidence which supports a necessary role for the C-terminal 
tail of occludin in correct targeting to the tight junction.  Structural and functional data 
suggest that the C-terminal tail of occludin can be divided into two sub domains.  The first 
150 amino acids proximal to the membrane (referred to as the proximal domain) are not well 
conserved among species and are not known to interact with any proteins (196).  However, 
the domain encompassing the last 150 amino acids (also known as the distal domain or the 
ZO-binding domain) is highly charged and conserved among species.  It is this region that 
binds directly to F-actin, ZO-1, ZO-2, and ZO-3 (197-201).  Further, investigators have 
crystallized the C-terminal tail of occludin and found that amino acids 416-522 are sufficient 
for ZO-1 binding (240) (Fig. 3.1).   
It has been shown that in mutant occludin lacking the extracellular homotypic binding 
sites, the C-terminal tail of occludin, especially the ZO-binding domain, is necessary and 
sufficient for its localization to TJs (203).  Chimeras of occludin expressing the membrane 
distal domain of occludin which contains the ZO-binding domain labeled the tight junction in 
MDCK cells (cells which contain ZO-1).  However, the membrane proximal region, which 
lacks the ZO-binding domain, localized to discrete puncta within the cells (203).  These 
constructs were also expressed in NRK fibroblasts, cells which do not contain occludin or 
claudins 1 or 2, nor do they generate tight junctions.  Again, the ZO- 
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Figure 3.1.  The amino acid sequence for the intracellular C-terminal tail of occludin.  Proximal domain (POC) 
consists of amino acids 265-372.  Distal domain (DOC) consists of amino acids 373-522.  ZO-1 binding domain 
consists of amino acids 416-522.  Tyrosines are in red, critical lysines in blue, and the amino acids sufficient for 
ZO-1 binding are bolded and underlined.   
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binding domain of occludin was sufficient to localize occludin to sites containing ZO-1, 
suggesting that the interactions with ZO proteins contribute to the targeting occludin at the TJ 
(203).   
Stable junctions are believed to exist in a dephosphorylated state and increased 
tyrosine phosphorylation of both AJ and TJ proteins can affect the stability of these junctions 
(69, 70, 212).  Src is a tyrosine kinase that localizes to the TJ, binds to ZO-1 (232) and can 
phosphorylate occludin in vitro (217).  Phosphorylation of the C-terminal tail of occludin by 
Src inhibits the binding of ZO-1, ZO-2, and ZO-3 and may be involved in Src-mediated 
disruption of TJs (217).  Therefore, we propose that the distal domain/ZO-binding domain of 
occludin may be the region which interacts with DEP-1.  The entire C-terminal tail of 
occludin contains 17 tyrosines, with 10 of them in the distal domain (Fig. 3.1).  Due to the 
large number of tyrosines we decided not to mutate individual tyrosines.  Instead, we used 
chimeras and truncation mutants of the cytoplasmic C-terminal tail of occludin to narrow 
down potential binding domains.  We expressed the mutants and conducted pulldown assays 
with the substrate-trapping mutant of DEP-1 to determine which domain was important for 
the interaction.  We found that tyrosines not only in the distal domain but also the proximal 
domain of the c-terminal tail are able to interact with DEP-1. 
 
Results 
 To investigate which domain/tyrosine residue(s) are important for occludin’s 
interaction with DEP-1 we used chimeras of the gap junction protein connexin32 and C-
terminal domains of occludin (203).  We saw binding of all constructs to GST-DEP-1 D/A, 
but not to GST with pervanadate treatment (Fig. 3.2).  We were concerned that the chimeras 
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could be binding to DEP-1 via the connexin32 component so we used the GST proteins in a 
pulldown assay from pervanadate treated MCF10A cells and probed with an anti-connexin32 
antibody.  Connexin32 is able to interact with the substrate trapping mutant of DEP-1 (data 
not shown) and thus we could not conclude whether the chimeras were binding due to 
interactions with connexin32 or occludin. 
With this knowledge, we developed truncation mutants of human occludin that were 
similar to those used by Mitic et al (203), but without the connexin32 transmembrane 
domains.  First, we generated these mutants in pEGFP-N2 but found the GFP from 
pervanadate-treated cells non-specifically interacted with the substrate-trapping mutant of 
DEP-1, again confusing our results (data not shown).  As a result, we generated similar myc-
tagged constructs (Fig. 3.3).  The myc tag does not contain a tyrosine and should not be 
phosphorylated by pervanadate treatment.  HEK 293ft cells were transfected with full length 
occludin as well as the mutants.  48-hrs post transfection cells were treated with pervanadate 
and lysates were used in a substrate trapping mutant pulldown.  Full length occludin, as well 
as all three mutants, bound to DEP-1 D/A (Fig. 3.4).    
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Figure 3.2. Connexin32 Chimeras of occludin interact with DEP-1 D/A.  The VSVG-connexin32 chimeras (A) 
DOC and (B) POC were transfected into HEK 293ft cells and 48 hours later they were treated with 100 µm 
pervanadate for 15 mins and lysed.  Lysates were used in a pulldown assay with GST or GST DEP-1 D/A, 
resolved by SDS-PAGE and membranes were probed with an anti-VSVG antibody.  *Although no POC appears 
in the lysate of B, a longer exposure confirmed that the protein is in fact expressed in the cells. 
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Figure 3.3.  Schematic of Myc-tagged Truncation Mutants of Occludin. Full length human occludin is depicted 
at the tope.  The transmembrane regions (TM) are gray with the extracellular loops dark blue and the small 
intracellular loop in light blue.   All truncation constructs are N-terminally tagged with myc.  The C-tail mutant 
contains both the POC and DOC.    
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Figure 3.4.  Truncation mutants of occludin interact with DEP-1 D/A.  HEK 293 ft cells were transfected with 
myc-tagged occludin truncation mutants.  Cells were treated with 100 µm pervanadate for 15 mins and then 
lysed.  1 mg of cell lysate was incubated with GST or GST DEP-1 D/A and samples were resolved with SDS-
PAGE and western blotting with a 9E10 myc monoclonal antibody or occludin antibody (for FL-Occ).   
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Discussion   
 This study examined whether an interaction between DEP-1 and occludin occurred by 
using truncation mutants of the occludin C-terminal tail.  We show that pervanadate 
treatment induced binding of all the occludin cytoplasmic truncations to DEP-1.  Based on 
the literature, we had hypothesized that the distal domain of occludin containing the ZO 
binding domain would be the most crucial (203).  However, in our experiments, the proximal 
domain was also able to interact with DEP-1 following pervanadate treatment.  One caveat to 
these experiments is that we have not examined binding of these mutants in cells not treated 
with pervanadate.  Previous work (chapter 2) has never demonstrated an interaction in 
untreated cells but we will examine this in the future.  In addition, we have not directly 
shown that pervanadate treatment induced phosphorylation of these mutants.  Since 
pervanadate treatment has phosphorylated full length occludin in previous experiments, it is 
expected to do so with these mutants but this will be tested.  The co-expression of 
constitutively active Src  and the myc-tagged POC and DOC mutants in HEK 293ft cells 
induced phosphorylation of the mutants, demonstrating they are capable of being 
phosphorylated (data not shown). 
With 17 tyrosines in the C-terminal tail, the possibility exists that DEP-1 may bind to 
multiple phosphorylation sites.  One major experimental factor that needs to be considered is 
the use of pervanadate to induce phosphorylation.  Pervanadate inhibits all tyrosine 
phosphatases and so causes a global increase in intracellular tyrosine phosphorylation levels.  
This treatment may cause the phosphorylation of certain tyrosines that under “normal” 
conditions are not phosphorylated, and result in false positive interactions.  A better way to 
better determine binding sites would be to induce phosphorylation with a known kinase, such 
as Src, that phosphorylates the C-terminal tail of occludin (217).  There are several Src 
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kinase recognition motifs in both the proximal domain as well as the distal domain which 
may be potential DEP-1 binding sites.  To test this, constitutively active Src could be co-
transfected with the truncation mutants and used in DEP-1 substrate-trapping mutant 
pulldowns to determine which, if any, Src phosphorylated tyrosines can bind to DEP-1.     
There are also several EGFR recognition motifs in the cytoplasmic tail of occludin, 
suggesting that the addition of EGF may stimulate this pathway and result in site-specific 
phosphorylation.  Preliminary experiments have been done examining EGF-induced 
phosphorylation of occludin; unfortunately, it has been difficult to show occludin 
phosphorylation specifically.  While generalized tyrosine phosphorylation of lysates 
increases with EGF treatment, it may require optimization of immunoprecipiation conditions 
in order to determine specific occludin phosphorylation.  In addition, EGFR is a substrate of 
Src and can be phosphorylated on Y845, an autophosphorylation site (241, 242).  As a result, 
Src may also be able to induce the phosphorylation of EGFR motifs indirectly.  One would 
have to keep this in mind when evaluating interaction data.  Regardless, these two kinases 
would more specifically phosphorylate the C-terminal tail compared to treatment with 
pervanadate and future studies will examine their effect on occludin-DEP-1 interactions. 
The C-terminal distal domain of occludin has been crystallized and from this study it 
was determine that amino acids 416-522 contain the binding site for ZO-1 and are important 
for occludin localization to cell-cell junctions.(240).   The surface charge profile found a 
large midsection of the distal domain which is highly basic and conserved among species.  
Double point mutations which changed lysine pairs to aspartic acid and reversed the charge 
of this section prevented the binding of ZO-1 to occludin (Lys433/511, Lys444/504, and Lys 
485/488).  A single point mutation at Lys 433 was also able to disrupt binding of ZO-1.  This 
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data suggested that the positive charged surface created by the lysine residues on the alpha 
helices of the distal domain of occludin created a binding site for the GUK domain of ZO-1 
(240).    Interestingly, both Lys 433 and 444 have a tyrosine residue adjacent to them (Fig. 
3.1).  We propose that because phosphorylation of one or both of these tyrosines will result in 
a negative charge in nearly the same location as the Lys->Asp mutation, phosphorylation 
might similarly disrupt occludin binding to ZO-1.  Therefore, future work should include 
mutating these two tyrosines to the phosphomimetic glutamic acid and determining if 
interaction with ZO-1 still occurs.  If these mutations successfully inhibit ZO-1 binding it 
suggests that tyrosine phosphorylation of these residues may be sufficient to attenuate the 
occludin and ZO-1 interaction.  In addition, mutations of Tyr432 and Tyr443 to 
phenylalanine will be used to determine if the occludin-DEP-1 interaction is dependent on 
phosphorylation of these residues.   
It has been shown previously that DEP-1 can selectively dephosphorylate several 
growth factor receptors in a site selective manner to control signaling (149, 152, 153, 226).  It 
is possible that DEP-1 can bind and dephosphorylate multiple tyrosines on the C-terminal tail 
of occludin, which could modulate protein-protein interactions (such as ZO-1), controlling 
tight junction protein complex formation and thus the barrier function of tight junctions.  The 
site selectivity that DEP-1 displayed in PDGF β-receptor dephosphorylation was 
predominantly determined by the primary amino acid sequence surrounding the 
phosphotyrosine.  Poorly dephosphorylated tyrosines have basic residues at positions -4 and 
+3 relative to phosphotyrosine (153, 226).  Lysine at position +3 seems to be the most crucial 
with regards to low affinity for the phosphotyrosine, with a lysine at +1 being better 
accepted.  For that reason, Tyr432 and Tyr443 are still acceptable potential 
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dephosphorylation sites for DEP-1 on occludin. Tyr443 might be the better of the two 
residues since it contains a leucine at +3 and a glycine at -4, both non-polar hydrophobic 
residues which have been shown to be favored by DEP-1 (226).  It is also possible that the 
susceptibility of dephosphorylation of a residue may be affected by the phosphorylation 
status of neighboring tyrosine residues.  This again emphasizes the role of site specific 
phosphorylation by kinases and upstream signaling pathways in deciding which PTP acts on 
a substrate at any given time.   
Our results suggest that several tyrosines in the C-terminal tail of occludin may be 
phosphorylated and consequently bound by the substrate trapping mutant of DEP-1.  Further 
work needs to examine DEP-1 binding after phosphorylation by specific kinase activity to 
avoid excessive, non-physiologic effects of pervanadate.  In addition, based on the 
identification of residues necessary for ZO-1 binding, specific tyrosines adjacent to critical 
lysines in the ZO-1 binding region will also be examined via point mutations studies.  
Mapping the residues necessary for DEP-1 interaction will help to clarify potential signaling 
pathways and kinases that DEP-1 activity may be counteracting.  In addition, we may 
determine additional kinases that may be involved in phosphorylation of occludin. 
 
Materials and Methods 
Constructs and Antibodies- VSVG-tagged full length human occludin and connexin 32-
occludin chimeras were obtained from Alan Fanning (University of North Carolina Chapel 
Hill) and are described previously (194, 203).    Myc-tagged truncations of the C-terminal tail 
of occludin were made similar to Mitic et al. (203).  The proximal C-terminal residues 265-
372 of occludin (POC), the distal c-terminal residues (373-522) (DOC) as well as the entire 
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C-terminal tail (265-522) (C-tail) were first inserted into pEGFP-N2 by amplifying this 
region and digesting with BglII and HindIII..   These constructs were then digested with 
BglII and KpnI and inserted into pCMV-Myc-J3 (modified Clontech vector from Jia Zhong 
at UNC-CH).  VSVG monoclonal antibody is from x.  9E10 myc monoclonal was 
supernatant produced in the Burridge Lab.    
 
Cell Culture and Transfections- HEK 293ft cells were cultured in Dulbecco's modified 
Eagle's medium-high glucose enriched with 10% fetal bovine serum and antibiotics.  Cells 
were transfected with Fugene6 (Roche Applied Science) according to the manufacturer’s 
instructions. 
 
GST fusion proteins and Substrate Trapping Pulldown—GST and GST-DEP-1 D/A were 
prepared as described in Chapter 2 material and methods.  HEK 293ft cells were transfected 
with myc-tagged occludin truncations or full length occludin and processed 48 hours later. 
Cells were treated with 100 μM pervanadate for 15 mins to induce phosphorylation prior to 
lysis.  Cells were rinsed twice in phosphate-buffered saline and lysed in a modified RIPA 
buffer (1% Tx-100, 0.5% DOC, 0.2% SDS, 150 mM NaCl, 20 mM Hepes ph 7.4, 2 mM 
EDTA, 10 μg/ml each aprotinin and leupeptin, and 1mM PMSF).  Insoluble material was 
removed by centrifugation. HEK 293ft lysates (1 mg) were incubated with 10 μg of GST or 
GST DEP-1 D/A for 1 hour at 4ºC.  Beads were washed in the modified RIPA buffer, 
resuspended in Laemmli sample buffer and analysed by SDS-PAGE and western blotting on 
PVDF membranes (Millipore). 
 
Chapter 4:  
 Focal adhesion proteins FAK and paxillin are substrates of DEP-1 
 
Summary 
FAK and paxillin localize to focal adhesions, points of adhesion between a cell and the 
extracellular matrix (ECM).  In response to adhesion to ECM proteins such as fibronectin, 
both proteins become tyrosine phosphorylated.  This tyrosine phosphorylation affects their 
activity and recruits binding partners.  Consequently, they are potential substrates for PTPs.  
In this study, FAK and paxillin bound to the substrate trapping mutant of DEP-1, and were 
found to be dephosphorylated by wild type DEP-1.  These data suggest that FAK and paxillin 
are substrates of DEP-1.  However, how DEP-1 regulates these proteins and their 
downstream signaling pathways is unknown.  Therefore, future studies will need to address 
this issue. 
 
Introduction 
 Post translational modifications such as tyrosine phosphorylation are critical to 
several signaling pathways downstream from cell-cell and cell-matrix adhesion.  
Phosphotyrosine levels are regulated by the balance between PTK and PTP activity.  
Although a number of kinases are known to be involved in increasing phosphorylation at 
sites of cell-matrix contact, the PTPs which act there are less understood.  In the previous 
chapters, substrates and signaling pathways involving DEP-1 and cell-cell adhesions were 
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discussed.   Here we examine DEP-1’s role in regulating the phosphorylation of proteins 
associated with cell-matrix adhesions.  
Focal adhesions are sites of strong adhesion to the ECM in cells grown in tissue 
culture.  They anchor stress fibers to the plasma membrane via integrins and are multiprotein 
signaling complexes for a large number of signaling pathways downstream of integrin 
mediated adhesions (60).  Both Src and focal adhesion kinase (FAK) are known to localize 
here and phosphorylate several of the focal adhesion proteins (4).  In addition, paxillin is a 
focal adhesion protein that is phosphorylated by several stimuli including integrin dependent 
cell adhesion and the tyrosine kinase activity of FAK and CAKβ (243-245).  Paxillin is a 
signaling molecule that plays an important role as an adaptor protein, recruiting cytoskeletal 
and signaling proteins to focal adhesions.  FAK and paxillin are known substrates for the 
phosphatases Shp-2, PTP-PEST and SAP-1 (18, 31, 236).  To test whether FAK and paxillin 
might also be substrates for DEP-1 we used the substrate trapping mutant of DEP-1 
(described in Chapter 2).  We found that they were in fact able to bind the DEP-1 D/A.  In 
addition, wild type DEP-1 was able to dephosphorylate the proteins suggesting FAK and 
paxillin are substrates of DEP-1.  We propose that DEP-1 is not only able to act on junctional 
proteins but may play a role in the regulation of cell-matrix adhesions as well as adhesion-
mediated signaling pathways. 
 
Results 
FAK and paxillin bind to the DEP-1 substrate trapping mutant 
We examined whether other known tyrosine phosphorylated proteins important in 
cell-matrix interactions are substrates of DEP-1.  We treated MCF10A cells with 
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pervanadate, a global PTP inhibitor, and used the lysate in a DEP-1 substrate trapping mutant 
pulldown.  Both FAK and paxillin were able to bind to DEP-1 D/A in a tyrosine 
phosphorylation dependent manner (Fig 4.1A), as well as a dose dependent manner (Fig. 
4.1B).  We wanted to determine if the interaction of DEP-1 D/A with FAK and paxillin was 
specific or if these proteins were substrates of additional PTPs.  Lysates of untreated or 
pervanadate treated MCF10A cells were incubated with GST fusion proteins of the substrate 
trapping mutants of DEP-1 (GST-DEP-1 D/A), PTP-PEST (GST-PTP-PEST D/A), and Shp2 
(GST-Shp2 C/S).  With a short exposure, DEP-1 D/A was the only PTP of those tested that 
was able to interact with FAK and paxillin and as observed previously (Fig. 4.1A) it did so in 
a tyrosine phosphorylation-dependent manner (Fig. 4.2A).  A longer exposure showed weak 
binding of paxillin to PTP-PEST (Fig. 4.2B).  Previous studies have shown that paxillin is a 
substrate of PTP-PEST (18ref, 246), although interaction with the substrate trapping mutant 
(PEST D/A) has not previously been demonstrated. 
DEP-1 can dephosphorylate FAK and paxillin in vitro 
 DEP-1 D/A can bind to both FAK and paxillin as determined by GST fusion protein 
pulldowns (Fig. 4.1 and 4.2).  We wanted to determine if FAK and paxillin were substrates 
for wild type DEP-1 as well as other wild type PTPs in vitro.  MCF10A cells were treated 
with pervanadate prior to lysis.  FAK and paxillin were immunoprecipated from the lysates 
and then incubated with purified GST-PTPs.  Phosphotyrosine levels of FAK and paxillin 
were analyzed by immunoblotting with anti-phosphotyrosine antibodies.  Wildtype DEP-1 
was able to dephosphorylate FAK and paxillin; where as other PTPs tested had minimal 
effects (Fig. 4.3A and 4.3B).  All PTPs used were tested for catalytic activity using the 
substrate pNPP.   
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Figure 4.1.  FAK and Paxillin interact with the substrate trapping mutant of DEP-1.  A. .  MCF10A cells were 
either left untreated (-) or were treated (+) with 100 µM pervanadate (PV) for 10 mins prior to lysis.  GST 
alone, GST-DEP-1 WT or GST-DEP-1 D/A fusion proteins (10 µg) were incubated with cell lysates and protein 
complexes were analyzed by SDS-PAGE and immunoblotting with FAK or paxillin antibodies.  B. FAK and 
paxillin bind DEP-1 D/A in concentration dependent manner. MCF10A cells were treated as described for A.  
Lysates were incubated with the indicated amounts of GST proteins and protein complexes were analyzed by 
SDS-PAGE and immunoblotting with antibodies to FAK and paxillin. 
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Figure 4.2.  FAK and Paxillin interact with DEP-1 with a higher affinity than other PTP trapping mutants.  
MCF10A cells were either left untreated (-) or were treated (+) with 100 µM pervanadate (PV) for 10 mins prior 
to lysis.  Lysates were were incubated with GST or the GST-fusion proteins of the substrate trapping mutants of 
DEP-1, PTP-PEST or Shp2.  Protein complexes were analyzed by SDS-PAGE and immunoblotted for FAK and 
paxillin. A.  Short time exposure shows DEP-1 D/A interacting with FAK and paxillin.  B.  Longer exposure 
confirms binding of paxillin, a known substrate, to PTP-PEST, but to a much lesser extent than DEP-1.   
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Figure 4.3.  DEP-1 dephosphorylates FAK and paxillin in vitro. MCF10A cells were treated with 100 µM 
pervanadate for 10 mins prior to lysis.  A. Paxillin and B. FAK were immunoprecipitated from lysates.  
Immunocomplexes were then incubated with GST or wildtype GST-PTP fusion proteins bound to glutathione 
sepharose for 30 mins at 65ºC.  Immunocomplexes were analyzed by SDS-PAGE and immunblotted with a PY-
20 antibody.  Membranes were then stripped and reprobed with the immunoprecipitated antibody (A. paxillin, 
B. FAK) to ensure equalized protein was immunoprecipitated.   
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Discussion 
 Here we have identified FAK and paxillin as two novel substrates for the receptor 
PTP DEP-1.  DEP-1 is a single pass transmembrane PTP which localizes to the plasma 
membrane and is enhanced at points of cell-cell adhesion.  DEP-1 has not been shown to 
directly localize at focal adhesions, but neither has PTP-PEST (247), a PTP known to 
dephosphorylate paxillin.  DEP-1 might be associated with a population of paxillin and/or 
FAK not located at focal adhesions.  Also, two PTPs related to DEP-1, SAP-1 and GLEPP1, 
negatively regulate intergrin-mediated signaling by dephosphorylating p130Cas and 
disrupting focal contacts and cytoskeletal components (236, 248).  Therefore, DEP-1’s 
expression at the plasma membrane as well as its homology to other PTPs with known focal 
adhesion substrates suggests that DEP-1 may interact with FAK and paxillin proteins in vivo.   
 DEP-1 may be both a positive and negative regulator of adhesion-mediated 
signaling.  DEP-1 binds c-Src and dephosphorylates the inhibitory tyrosine 529, thereby 
increasing Src kinase activity (172).  Adhesion, along with tyrosine phosphorylation of both 
FAK and paxillin, were increased in these cells compared to untransfected or cells expressing 
the catalytic inactive mutant (DEP-1 C/S).  Inhibition of c-Src activity with PP2 decreased 
these responses, suggesting DEP-1 may be positive regulator of Src acvitiy in the context of 
integrin-mediated adhesion and may increase levels of phosphotyrosine in FAK and paxillin 
(172).  Additional data have also confirmed that over expression of DEP-1 increases cell 
adhesion (157), strengthening this model.   
However, DEP-1 may also negatively affect adhesion-mediated signaling cascades.  
When DEP-1 was over-expressed in NIH 3T3 fibroblasts there was a reduction in association 
of Src with PDGFR-β concomitant with a decrease in FAK phosphorylation (92).  
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Furthermore, 48 hours after induction of DEP-1 expression, virtually no paxillin containing 
focal adhesions were seen in the fibroblasts, however, the control cells appeared normal.  
DEP-1 cells were able to make adhesions with the extracellular matrix protein fibronectin, 
however, the cells had smaller, dot like peripheral structures which were short lived and 
failed to induce phosphorylation of FAK compared to control cells.  These focal complexes 
were able to form, but did not mature into stable focal adhesions like control cells.  
Moreover, DEP-1 cells exhibited decreased migration in response to PDGF and were much 
smaller and more rounded demonstrating both a cell spreading and cell migration defect (92).    
Therefore, several signaling pathways may be controlled by DEP-1.  DEP-1 may be 
regulating phosphorylation of FAK indirectly by dephosphorylating PDGFR-β, thereby 
attenuating the PDGFR-β-Src interaction, and modulating Src activity and other downstream 
signaling pathways.  Also, DEP-1 over expression might be inhibiting Rho GTPase activity.  
Previous studies found PTP-PEST decreased Rac1 activity and inhibited cell migration by 
controlling the phosphorylation levels of GEFs and GAPs (10, 11).  Several GEFs and GAPs 
for the Rho family are regulated by tyrosine phosphorylation, including the Rac GEF VAV2 
and the Rho GAP p190RhoGAP (249, 250).  These proteins may be substrates for DEP-1 as 
well.  Interestingly, our data provides evidence that DEP-1 could also directly be 
dephosphorylating FAK and paxillin.  In this way, DEP-1 could either prevent focal adhesion 
assembly or disassembly by regulating tyrosine phosphorylation of specific residues in FAK.  
Modulation of paxillin phosphorylation levels may alter its interactions with downstream 
effectors and affect signaling pathways.  There are several possible mechanisms and 
signaling pathways by which DEP-1 could be exerting an effect on phosphorylation levels of 
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FAK and paxillin.  Further studies will need to be conducted to determine if these 
mechanisms are influenced by cell type, matrix, or additional stimuli. 
Paxillin is a known substrate for PTP-PEST (18, 246).  We found that the substrate 
trapping mutant of DEP-1 was able to bind to paxillin and wild type DEP-1 can 
dephosphorylate it, suggesting paxillin is also a substrate of DEP-1.  Although paxillin may 
be a substrate for both PTPs, the mechanisms by which the protein-protein interactions occur 
between paxillin and the PTPs might be different.  PTP-PEST binds paxillin via its C-
terminal non-catalytic domain and paxillin’s C-terminal LIM domains (18, 246, 251).  
Therefore, the non catalytic domain interaction recruits paxillin to PTP-PEST and facilitates 
paxillin’s dephosphorylation (246).  Previous work was unable to show an interaction 
between the substrate trapping mutant (C/S) of PTP-PEST with paxillin (251).  However, the 
substrate trapping mutant (D/A) of PTP-PEST was able to weakly interact with paxillin in 
our study.  The C/S mutant is known to be a less efficient trapping mutant (8) and so it could 
be a combination of the different mutation and a larger amount of GST fusion protein used in 
the pulldowns that enabled us to see this interaction.  Although we are seeing a small amount 
of paxillin binding to GST-PTP-PEST D/A, the primary interaction between these two 
proteins is driven independently of the PTP-PEST catalytic domain.  On the other hand, 
DEP-1 D/A showed a very robust interaction with paxillin even when low levels of GST-
DEP-1 were used (Fig. 4.1), suggesting paxillin may be interacting directly with the catalytic 
domain of DEP-1 and not through an accessory binding event.   Testing the ability of PTP 
inhibitor orthovanadate to block the interaction between DEP-1 and paxillin will help to 
determine whether paxillin is exclusively interacting via DEP-1’s catalytic domain.  
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FAK has previously been shown to be a poor substrate for PTP-PEST (41).  We have 
confirmed this data, demonstrating that FAK binds neither the PTP-PEST trapping mutant, 
nor is it dephosphorylated by wild type PTP-PEST in vitro (Fig. 4.2A and 4.3B).  However, 
FAK is a very strong candidate substrate for DEP-1.  FAK not only interacts with the 
substrate trapping mutant of DEP-1 after pervanadate treatment, but FAK is 
dephosphorylated by recombinant wild type DEP-1 in vitro (Fig. 4.1 and 4.3B).  In addition 
to the possibility that DEP-1 acts on FAK at focal adhesions, recent work has placed FAK at 
cell-cell junctions.  FAK has been shown to be important in junction as they form.  For 
example, when Hela cells were depleted of FAK, N-cadherin mediated cell-cell contacts 
were inhibited in subconfluent cultures (252).  Expression of constitutively active FAK in 
NBT II cells resulted in no change in junctions; however, expression of inactive FAK 
drastically diminished cell-cell adhesions at early time points following a calcium switch 
(253).  During junctional reassembly, active FAK could be seen at junctions in only 
approximately 10% of cells and it was never seen in already confluent cultures, suggesting 
FAK may only transiently associate at junctions (253).  Therefore, FAK may be involved in 
the formation and possible stabilization of cell-cell adhesions.  It will be interesting to test if 
DEP-1 may regulate phosphorylation of Tyr 397 and influence junction formation. 
Additionally, identifying other potential tyrosine residues dephosphorylated by DEP-
1 would aid in the delineation of the role of DEP-1 in paxillin and FAK related focal 
adhesion and cell-cell junction signaling.  There are numerous phospho-specific antibodies 
available for FAK and paxillin and it would be very informative to perform DEP-1 substrate 
trapping mutant pulldowns to determine which residue(s) is binding to the PTP.  Also, DEP-1 
could be overexpressed or reduced with siRNA in cells and phosphorylation changes could 
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be examined.  To further clarify signaling pathways, phosphorylation could be assessed 
following various stimuli.  For example, following a calcium switch, phosphorylation levels 
of several tyrosine residues in FAK were examined.  Little or no change was found with 
tyrosines 397, 576, 577, or 925.  However, two hours after calcium replenishment Tyr 861 
displayed elevated phosphorylation (253).  This increase in phosphorylation was dependent 
on the interaction with E-cadherin.  These findings make tyrosine 861 an attractive candidate 
residue DEP-1 may regulate with regards to cell-cell contact formation.  Another interesting 
residue to examine is Tyr 925.  As described in Chapter 1, phosphorylation of Tyr 925 in 
FAK is necessary to induce an interaction with dynamin at focal adhesions, a critical step in 
focal adhesion disassembly (62).  It would be interesting to examine this residue and focal 
adhesion disassembly in DEP-1 knockdown cells. 
 Although we see complete dephosphorylation of FAK and paxillin when incubated 
with wildtype DEP-1 it is possible that the pervanadate treatment only phosphorylated certain 
tyrosines.  Also, DEP-1 may preferentially dephosphorylate certain residues in vivo, but the 
use of high levels in the in vitro assay may result in total dephosphorylation.  The 
experiments presented here were conducted with confluent epithelial cells.  These cells do 
not contain a large amount of focal adhesions, if any.  Future experiments will examine DEP-
1 substrates in fibroblast cell lines. 
There is the possibility that there might be cross talk between cell-cell junctions and 
focal adhesions.  High RhoA is disruptive to AJ formation (110-112).  As junctions from, 
Rac1 activity is increased and RhoA activity is decreased as direct response to cadherin-
cadherin engagement (115).  Cadherin engagement induces src-dependent tyrosine 
phosphorylation of p190RhoGAP, thus leading to the observed decrease in RhoA (116).  
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Epithelial cells need low levels of RhoA to reduce their intracellular tension and contractility 
and promote the formation of cell-cell adhesions (254).  Low RhoA levels also turn off focal 
adhesion signaling.  DEP-1 may be involved in regulating both cell-cell junction and focal 
adhesion signaling at the same time.   
 
Methods and Materials 
Cell Culture-- MCF10A cells were grown in a 1:1 mixture of Dulbecco’s modified Eagle’s 
medium (DMEM) and F12/Ham medium supplemented with 5% horse serum, 20 ng/ml 
EGF, 0.01 mg/ml insulin, 500 ng/ml hydrocortisone, 100 ng/ml cholera toxin and antibiotics. 
 
Constructs and Antibodies—GST DEP-1 constructs were generated as described in Chapter 
2.  GST PTP-PEST constructs were kindly provided by Sarita Sastry (University of Texas 
Galveston).  The monoclonal PY-20 was purchased from Santa Cruz Biotechnology.  
Monoclonal FAK and paxillin antibodies were from BD Transduction labs. 
 
GST fusion proteins-- Expression of the fusion proteins in Escherichia coli were performed 
as previously described in Chapter 2. 
 
Substrate Trapping Pulldown-- MCF10A cells were either left untreated or treated with 100 
μM pervanadate (phosphatase inhibitor) for 15 mins prior to lysis.  Cells were rinsed twice in 
phosphate-buffered saline and lysed in a modified RIPA buffer (1% Tx-100, 0.5% DOC, 
0.2% SDS, 150 mM NaCl, 20 mM Hepes ph 7.4, 2 mM EDTA, 10 μg/ml each aprotinin and 
leupeptin, and 1mM PMSF).  Insoluble material was removed by centrifugation. MCF10A 
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lysates (1 mg) were incubated with 10 μg of GST proteins (Figure 4.1) or 100 µg GST 
proteins (Figure 4.2) for 1 hour at 4ºC.  Beads were washed in the modified RIPA buffer, 
resuspended in Laemmli sample buffer and analysed by SDS-PAGE and western blotting on 
PVDF membranes (Millipore). 
 
Dephosphorylation Assays-- MCF10A cells were treated with 100 µM pervanadate for 15 
mins and lysed in the modified RIPA buffer plus 10 μg/ml each aprotinin and leupeptin, 
1mM PMSF, and 5 mM iodoacetic acid (IAA).  After incubation of the lysates on ice for 10 
mins, DTT was added at a final concentration of 10 mM for another 10 mins on ice to 
inactivate the IAA.  Lysates were clarified and FAK or paxillin was immunoprecipitated 
from 1 mg lysate with 2 µg antibody for 2 hours at 4ºC.  IPs were washed, resupsend in a 
succinate buffer (50 mM succinate pH 6.0, 50 mM NaCl, 1 mM EDTA, 1 mM DTT) and 
incubated with 1 μg glutathione-sepharose bound GST-PTPs for 30 minutes at 30ºC.  The 
reaction was quenched washing 1 time in the succinate buffer and resuspending in Laemmli 
sample buffer.  The immune complexes were run on SDS-PAGE gels and analyzed by 
western blotting using the PY-20 antibody, FAK monoclonal antibody or paxillin 
monoclonal antibody. 
Chapter 5: 
Conclusions and Future Directions 
 
A key element regulating cell-cell and cell-matrix adhesion is tyrosine 
phosphorylation of proteins at intercellular junctions and focal adhesions.  In this 
dissertation, DEP-1 has been shown to bind to and dephosphorylate proteins located at both 
locations.  In chapter 2, occludin and ZO-1 were identified as novel substrates for the RPTP 
DEP-1.  These proteins appear to be substrates specific for DEP-1 and potentially a related 
PTP, SAP-1.  DEP-1 and SAP-1 are extremely similar to each other, each with 8 fibronectin 
type III repeats and a single catalytic domain (89, 230).  Therefore, occludin and ZO-1 might 
be substrates specific to this particular family of PTPs.  It would be interesting to see if VE-
PTP is also able to act on these TJ proteins.  We also provided evidence that the over-
expression of DEP-1 increased transepithelial electrical resistance in confluent monolayers 
and reduced paracellular flux of FITC-dextran following a calcium switch.  Through 
dephosphorylation of junctional components, DEP-1 may enhance the stability of protein 
complexes involved with maintaining junctional integrity.  Future work will focus on 
identifying where DEP-1 interacts with occludin (Chapter 3).  This would enhance our 
understanding of the specificity of DEP-1’s catalytic domain, including its recognition of the 
amino acid sequence surrounding the phospho-tyrosine.  It is possible that there are multiple 
binding and dephosphorylation sites on occludin, depending on upstream kinase activity.  We 
propose that Src kinase phosphorylates occludin and disrupts its interaction with DEP-1, but 
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would also like to test growth factor receptors such as EGFR.  In addition, Chapter 4 
discussed the identification of FAK and paxillin as potential substrates for DEP-1.  
Phosphorylation of both FAK and paxillin occurs downstream from integrin-mediated 
signaling and DEP-1 may therefore be involved with these pathways as well.  Also, 
phosphorylation of FAK occurs at cell-cell junctions during junction reassembly (253) and 
may be another way in which DEP-1 may control cell-cell adhesion.  Experiments still need 
to be conducted in order to determine exactly how DEP-1 is controlling physiological 
processes associated with dephosphorylation of these focal adhesion proteins. 
 The work presented here has demonstrated a role for the RPTP in controlling cell 
adhesions in epithelial cells.  The following chapter will discuss directions for future research 
regarding DEP-1 and other RPTPs.   First, we will focus on the possibility that RPTPs are 
involved in the process of leukocyte transmigration.  Next we will examine the importance of 
the extracellular domain in regulating PTP activity.   Finally, we will end with a look at PTPs 
in cancer and the development of PTP inhibitors. 
 
DEP-1 as a regulator of leukocyte transmigration 
The vascular endothelium controls the passage of macromolecules and immune cells 
across it.  There are two known mechanisms for leukocyte migration across the endothelium: 
transcellular and paracellular.  Direct evidence supports the existence of transcellular 
migration (i.e. through a cell), although it is believed to occur in only 5-10% of 
transmigratory events in-vitro (255).  Thus, the predominant route for leukocyte 
transmigration is paracellular migration, where leukocytes migrate between adjacent 
endothelial cells through their junctions (256).  In the resting state, the endothelium 
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maintains its barrier properties and prevents the passage of cells out of the bloodstream and 
into tissues.  When an inflammatory response is elicited, however, the properties of the 
endothelium change and leukocytes are able to adhere to and migrate through gaps at the 
intercellular junctions.  The final step in the adhesion cascade of leukocyte transmigration is 
diapedesis, or the crawling of the leukocyte between adjacent endothelial cells.  In order for 
this to occur, the leukocyte must breach a physical barrier of junctional structures including 
TJs and AJs (for review see (257)).  It has been shown that the adhesive strength of the TJ 
and AJ is regulated by the tyrosine phosphorylation levels of their protein components.  An 
increase in tyrosine phosphorylation dissociates the junctional complexes from the actin 
cytoskeleton and reduces junctional integrity (73, 74, 214, 217).  Therefore, regulation of 
tyrosine phosphorylation levels of junctional components is an important mechanism for 
regulating both the stability and permeability of tight and adherens junctions and thus may 
affect the ability of leukocytes to transmigrate.  
Several PTPs have been shown to localize to junctions as well as interact with 
members of the cadherin-catenin complex (235).  Specifically, PTPµ, DEP-1, PTP1B, and 
VE-PTP are found in endothelial cell junctions (81, 87, 90, 258).  Previous studies in our lab 
revealed that leukocyte transmigration increased VE-cadherin phosphorylation at residues 
specific for p120ctn and β-catenin binding (259).  When these residues were mutated to 
phenylalanine, transmigration was reduced, directly indicating the involvement of tyrosine 
phosphorylation of junctional proteins during leukocyte TEM (259).  Several junctional 
binding partners for DEP-1 have been discovered such as β-catenin, plakoglobin and p120- 
catenin (80) and now occludin and ZO-1.  Our preliminary data demonstrates that VE-
cadherin may also be a substrate for DEP-1.  With numerous junctional proteins as 
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substrates, it is likely that DEP-1 is involved in modulating phosphorylation of endothelial 
junctional proteins.  Using the same phospho-specific antibodies used by Allingham et 
al.(259), we plan to explore whether DEP-1 interacts with the phosphorylated VE-cadherin 
residues necessary for catenin binding.  We also plan to evaluate the effect that DEP-1 
expression has on leukocyte TEM, and the phosphorylation of other substrates during the 
process of transmigration. 
One manner by which DEP-1 activity might be altered during TEM is through 
binding of its extracellular domain.  Receptor PTPs are proposed to act as adhesion receptors, 
transducing outside-in signaling.  Initially we were interested in exploring the extracellular 
binding partners of DEP-1, especially those involved with leukocyte transendothelial 
migration (TEM).  One possible interaction would be a homophilic, trans interaction of DEP-
1 on adjacent endothelial cells.  Other RPTPs are known to interact in homophilic 
interactions (84, 96, 120), which stabilize the protein at cell-cell contacts (94).  The 
clustering of RPTPs at the plasma membrane brings the catalytic domain into close proximity 
with junctional protein substrates, promoting a net tyrosine dephosphorylation and potential 
strengthening of junctional integrity (78, 80, 94). Another possibility is that DEP-1 is 
interacting with itself on a migrating leukocyte.  Hematopoietic cells express varying 
amounts of DEP-1 (CD148) (165-167), with white blood cells, in particular monocytes and 
macrophages, expressing very high levels of DEP-1 (165, 166).    Therefore, DEP-1 on 
endothelial cells could be binding to DEP-1 on leukocytes and this interaction could affect 
the catalytic activity of DEP-1, altering phosphorylation of junctional proteins.  A third 
hypothesis is that DEP-1 can form heterophilic interactions with other cell adhesion 
molecules on endothelium, leukocytes or both.  JAMs are not exclusively found on cells that 
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form TJs, but are also on leukocytes (182).  As a result, the extracellular domain of JAMs 
might interact with the extracellular domain of DEP-1 and aid in controlling TEM.  Other 
potential targets are the extracellular domains of cadherins and growth factor receptors.   
A number of extracellular ligands have been identified for a few RPTPs, including 
homophilic and heterophilic interactions (260, 261),  however, ligands have not been 
identified for the majority of RPTPs.  Although no extracellular ligands for DEP-1 have been 
identified yet, a recent study suggests that an undefined ligand is found in Matrigel, a 
commercial ECM protein preparation (100). Association of DEP-1 with Matrigel increased 
the intracellular phosphatase activity of DEP-1 (100).  In addition, antibody-induced 
ectodomain oligomeriztion of DEP-1 also increased its catalytic activity (150).  Therefore, 
interaction of DEP-1’s extracellular domain with itself or binding an extracellular protein 
may result in an increase in PTP activity.  In the model of leukocyte transmigration, 
increased activity of DEP-1 due to interactions with proteins on adjacent endothelial cells 
would allow for the dephosphorylation of junctional proteins, reformation of TJ and AJ 
complexes, and enhanced barrier function of endothelial cells.  On the other hand, we would 
expect that binding to a leukocyte protein would inhibit PTP activity, allowing for increased 
phosphorylation of AJ and TJ proteins and loss of junctional integrity.  It is possible that such 
a ligand exists and is awaiting discovery.  Other attractive PTPs canditates for a role in 
leukocyte TEM are PTPµ and the vascular endothelial specific VE-PTP. 
 
The Importance of RPTP Extracellular Domains 
Signal transduction from RTKs emanates from the ligand binding extracellular 
domain.  Ligand binding induces dimerization and autophosphorylation of the intracellular 
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tyrosines leading to activation and recruitment of downstream targets (262).  In contrast, 
mechanisms controlling RPTP enzyme activity are unknown (263).  RPTPs have 
extracellular domains that resemble other known cell adhesion molecules and it has been 
proposed that they can be involved in homo- and heterotypic intercellular binding (125).  As 
stated in the introduction, RPTPs have traditionally been considered to be active as 
monomers and inactive when dimerized (125).  This is known to be true for RPTPα (127-
129), CD45 (264), SAP-1 (265), and PTPBR7 and PTP-SL (266).  Other PTPs are able to 
dimerize, but it is unclear whether this dimerization affects their catalytic activity.  In most 
cases, dimerization is independent of the catalytic domain and occurs through the 
extracellular domain or transmembrane domain. In fact, the transmembrane domain of PTPλ, 
PTP LAR, PTPα, PTPγ, GLEPP1, and DEP-1 are able to homodimerize in Escherichia coli 
membranes, albeit to different extents (267).  In addition, several studies in eukaryotic cells 
have demonstrated that the transmembrane domain of PTPα is necessary and sufficient for 
mediating receptor dimerization (127, 129, 268). Furthermore, artificial induction of 
dimerization affects the enzyme activity of CD45, RPTPα, and DEP-1 (128, 150, 264).     
Inhibition of the catalytic activity of PTPα has been proposed to occur by the catalytic 
domain of one PTPα being blocked by specific contacts with an inhibitory wedge domain 
from the membrane proximal region of the other PTPα partner (269). The residues that 
compose this structure in PTPα are conserved among other RPTPs including PTPµ and PTP-
LAR (130, 131).  However, structural analysis of the membrane-proximal catalytic domain 
of PTPµ and the entire cytoplasmic domain of PTP-LAR reveal that the inhibitory interaction 
between the catalytic domain and the wedge are not observed (130, 131). It remains to be 
determined whether the wedge domain can interact with the catalytic domain of other RPTPs, 
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proposing the possibility that this method of dimerization-induced inhibition may not be a 
universal mechanism regulating RPTP activity.     
Interestingly, introduction of a cysteine residue in the extracellular juxtamembrane 
domain of RPTPα results in disulfide bond formation and dimerization (128).  Depending on 
the exact location of the cysteines, the dimers are either active or inactive (128).  This 
suggests that the orientation in which the extracellular domain dimerizes affects the 
intracellular orientation of the PTP domain and can influence its activity.  SAP-1 is a RPTP 
which naturally contains an extracellular domain with several cysteine residues capable of 
forming disulfide bonds.  Altering the redox state of the SAP-1 can reversibly control its 
dimerization and its activity (265).  Moreover, PTPσ has two major isoforms, differing 
slightly in the number of their FNIII repeats.  The alternative arrangements of the 
extracellular domain alters the ligand binding specificities of this PTP (270), potentially by 
changing the rotational conformation of the N-terminal extracellular domain.  It is also 
possible that modifications of the cytoplasmic domains, such as phosphorylation or 
oxidation, also results in changes in the rotational coupling within RPTP dimers and alters 
ligand-binding properties.  RPTPα-D2 (catalytic domain 2) changes its conformation in 
response to the cellular redox state of the cell (268), implying RPTPs may not only have the 
capacity for outside-in signaling but also inside-out signaling (261).  Collectively, subtle 
changes in the relative orientation of RPTP dimers in both the extracellular and intracellular 
domains may be able to determine whether the PTP is active or inactive, providing a new 
mechanism for regulation.   
   The increasing complexity of factors that affect dimerization forces us to look at 
RPTP dimerization, ligand binding and activity more closely.  How exactly are RTPs being 
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turned on and off?  Perhaps the answer will never be as simple as it is for RTKs.    
Nevertheless, the extracellular domains of PTPs appear to be very important in determining 
their activity and downstream signaling pathways.  Does the extracellular domain of a RPTP 
dictate whether dimerization activates or inhibits it?  Or does the dimerization state of RPTPs 
affect their ability to bind to extracellular ligands, adding yet another level of complexity?  
Too many questions are left unanswered for us to clearly state how RPTP activity is 
regulated.  In the end, the role of the extracellular domain may be PTP specific or even cell 
type specific, determined by the availability of ligands and signaling partners.  
   
PTPs in Cancer 
Cell adhesion plays a critical role in the process of metastatic tumor dissemination.  
Loss of cadherins expression and other cell adhesion molecules is a trademark sign of 
metastatic cells (271).  Tumor development is associated with remodeling of the both TJs and 
AJs.  Neoplastic cells escape from the constraints imposed on them by intercellular junctions 
and adopt a migratory behavior.  Increased phosphorylation at junctions leads to disassembly 
of AJ and TJ protein complexes as well as decreased junctional integrity.  Thus, PTP activity 
may influence invasion and metastasis in certain cancers.  
Loss of function mutations 
Loss of function of PTPs has been associated with cancer progression.  Less than one 
third of point mutations in PTPs occur within the PTP domain, suggesting that loss of 
function is indirectly related to the structure of the catalytic domain (272).  For example, 
RPTPρ is frequently mutated in human cancers including lung, colon, and skin (273).  In 
colorectal tumor isolates, mutations were found in both the intracellular and extracellular 
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domains (273).  Intracellular mutations diminished PTP activity as expected and it was 
proposed that mutations in the extracellular domain may alter protein-protein interactions 
(273).  Five mutations were mapped to residues located in the MAM and immunoglobulin 
domains of RPTPρ, an area necessary for adhesion in PTPµ (274-276).  Subsequently, these 
mutations were introduced into SF9 cells and impaired the homophilic interaction of PTPρ as 
demonstrated by the reduction of cell aggregate formation.   This suggests that the mutations 
found naturally occurring in cancers were loss of function mutations (277).  Disruption of 
protein-protein interactions may affect several signaling pathways and promote tumor 
migration and metastasis.  A number of mutations in the DEP-1 gene, PTPRJ, also create 
coding polymorphisms and have been found in human cancers.  Mutations in the 
extracellular domain are located in the 2nd and 8th fibronectin repeats (Fig. 1.4) (142, 163). 
These mutations are predicted to occur in exposed regions available for protein-protein 
interactions and could affect ligand binding, dimizeration, and downstream signaling 
pathways (163).  Currently, the effects of these mutations have not been analyzed but it 
would be of interest to express them and compare effects of junctional integrity to wildtype 
DEP-1.  Additionally, point mutations located in the proline-rich domain of PTP-PEST have 
been found in breast cancer cell lines (278).  Two of these mutations enhance PTP catalytic 
activity whereas the third mutation inhibits activity (278).   Shp-2 is yet another PTP in 
which mutations are associated with certain cancers including juvenile myelomonocytic 
leukemia, lung and colon cancer (279, 280).  Several mutations in the N-terminal SH2 
domain disrupt the inhibitory interaction with its catalytic domain, leading to activation of 
Shp-2 (281, 282).  Therefore, mutations in non catalytic domains can both activate and 
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inhibit PTP activity, whether through altering localization or interrupting inter- or 
intramolecular interactions.  
Loss of protein expression  
 In addition to loss of function mutations, loss of PTP expression is observed in 
several cancers.  SAP-1 levels were down-regulated in advanced human hepatocellular 
carcinoma  and (283).  Protein expression correlated with the differentiation state of the cells, 
with normal tissue or well-differentiated HCC expressing similar or higher levels than non-
cancerous tissue, and poorly differentiated HCC having reduced levels of SAP-1    (283).  
DEP-1 expression has been shown to be drastically reduced in multiple cancer cell lines and 
human cancers including thyroid, breast, pancreatic and colon cancers (139-142, 164). In 
addition, LOH of locus for the DEP-1 gene is frequent in human cancers (163).  Therefore, 
DEP-1 has been proposed to act as a tumor suppressor by inhibiting cell proliferation.   
Studies have re-expressed DEP-1 in cancer cell lines lacking endogenous DEP-1 and found 
that there was a profound inhibition in cell proliferation (139-142, 164). 
Besides controlling proliferation, DEP-1 may be inhibiting metastasis by reducing 
cell motility, as shown in Chapter 4, by means of regulating integrin-mediated signaling 
pathways as well as stabilizing cell-cell junctions through dephosphorylation of tight junction 
proteins (Chapter 2).  Supported by other cancer models such as colon, pancreatic, and 
thyroid cancer (140-142, 164), we proposed that breast cancer cell lines would have reduced 
DEP-1 levels as well.  The protein expression levels of DEP-1 were examined in normal-like 
breast epithelial cells (MCF10A) as well as dedifferentiated breast cancer cells (MCF7) and 
metastatic breast cancer cells (MDA-MB-231).  Cells were lysed and total protein 
concentrations were normalized.  Lysates were immunoblotted for DEP-1 and junctional 
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proteins β-catenin and E-cadherin.  As seen in Fig. 5.1, DEP-1 protein levels increased as 
junctional proteins decreased.  We anticipated seeing a decrease in junctional proteins in the 
metastatic cells, yet we hypothesized that DEP-1 levels would also decrease.  One 
explanation for our observed increased in DEP-1 is that the cell’s feedback machinery is 
trying to counterbalance overgrowth by DEP-1 expression, but perhaps another signaling 
pathway is overriding it.  Another explanation is that the DEP-1 expressed in the MDA-MB-
231 has disregulated activity possibly due to one of the point mutations found in cancer 
(163).  To try and determine whether this was a possibility, we compared the catalytic 
activity of DEP-1 from MCF10A and MDA-MB-231 cells.  In this preliminary experiment, 
DEP-1 was immunoprecipitated from an equal amount of total protein from both cell types.  
Half of the precipitated protein was run on a gel to determine the amount of DEP-1 
immunoprecipitated and the other half was used in a pNPP assay.   Significantly more DEP-1 
immunoprecipitated from the MDA-MB-231 cells compared to the MCF10A cells (Fig. 
5.2A).  Interestingly, the catalytic activity of DEP-1 from the MCF10A cells was higher than 
the metastatic cells (Fig. 5.2B).  Considering that substantially more DEP-1 was 
immunoprecipitated and thus used in the MDA-MB-231 activity assay, we can conclude that 
DEP-1 in the MDA-MB-231 cells may have a considerable reduction in catalytic activity.  
We plan to repeat this as well as to examine mRNA levels of DEP-1 in these cell types to 
determine whether transcription is altered.  It would also be interesting to compare substrates 
for DEP-1 in normal versus breast cancer cell lines.     
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Figure 5.1.  DEP-1 protein levels are increased in breast cancer cells compared to normal-like breast epithelial 
cells.  Equalized total cell lysate from MCF10A, MCF7, and MDA-MB-231was immunoblotted with antibodies 
against DEP-1, β-catenin, and E-cadherin.   
 
 118
 
 
 
 
 
Figure 5.2.  DEP-1 from breast cancer cells has decreased PTP activity compared to normal breast epithelial 
cells.  DEP-1 was immunoprecipitated from both MCF10A and MDA-MB-231.  The immunoprecipiation was 
divided in two and either A. run on a gel and immunoblotted for DEP-1 or B. used in a pNPP activity assay. 
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Over expression of DEP-1 in Cancer  
With our result of increased DEP-1 in breast cancer cells, we were curious if other 
PTPs may be up regulated in cancers.  One study found an increase in total PTP activity in 
breast cancer (284).   Another group has shown that DEP-1 levels can vary in breast cancer 
cells lines, with MDA-MB-231 being one of the cell lines which exhibited the highest 
expression of DEP-1 (227).  SAP-1 is overexpressed in human colorectal cancer (285) while 
PTP1B overexpression was established in breast tumor tissue (286).  In addition, PTP-LAR 
mRNA and protein levels were markedly increased in breast cancer cell lines and tissues 
(287) while another study found that one third of the primary breast carcinomas tested were 
characterized by strongly eleveated RPTPα levels (288).  Interestingly, these high protein 
levels were associated with low tumor grade (ER positive) and cells experimentally induced 
to have high PTPα cells showed delayed tumor growth and metastasis in mice (288).  
Increased PTP-LAR and PTP1B levels were found in human breast cancer as a consequence 
of expression of the activated neu oncogene.  The amount of the PTP directly correlated to 
the expression of neu (289).  Likewise, knockdown of PTPα induced apoptosis in ER 
negative but not ER positive breast cancer cells (290).  These results insinuate that the 
genetic background of the cancer may regulate the expression level of the PTP as well as the 
signaling pathways in which the PTP is involved.  Further studies will need to confirm this 
but it proposes an intriguing possibility. 
 
PTP inhibitors 
Over the last several years, PTP inhibitors have begun to be developed.  Researchers 
are striving for a highly potent, yet selective small molecular inhibitor.  Two main concerns 
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exist.  First, PTPs contain a highly conserved active site, therefore obtaining inhibitors that 
selectively targets one PTP will be difficult.  Second, a large number of side effects could 
occur because a single PTP might regulate multiple signaling pathways or a key pathway 
might be regulated by several PTPs (291).  To address the first concern, researchers are 
looking for secondary binding sites in regions adjacent to the catalytic domain.  Perhaps 
inhibitors targeted to these areas will enhance the inhibitors affinity and selectivity.   
There are several PTP1B inhibitors currently being produced.  PTP1B counteracts 
signaling through the insulin receptor (292), making a small molecule inhibitor of PTP1B a 
promising treatment for type 2 diabetes.  Recently, mice from the well- established breast 
cancer mouse model (NDL2) were crossed with PTP1B deficient mice.  Mice lacking PTP1B 
in this background displayed a reduced rate of tumor development, number of tumors, and 
lung metastases (293).  Treatment of PTP1B +/+ mice with a PTP1B specific inhibitor also 
delayed the onset of mammary tumors (293).  Consequently, PTP1B inhibitors might also 
used in cancer treatment, especially in ErbB2-positive breast cancers.  Shp-2 has also been 
identified an oncogenic PTP and small molecule inhibitors are currently being developed 
(294).   Although progress is being made for each of these PTPs, inhibitors for PTPs are still 
far behind the RTK inhibitor field.         
For RPTPs, an alternative to interfering with the catalytic domain would be to target 
the extracellular domain and control activity by ligand-ectodomain interactions (137).  The 
structural diversity of the extracellular domain makes it an attractive target to develop 
specific inhibitors.  Antibodies to CD45 extracellular domain have already been shown to 
have the potential to inhibit CD45 activity (295, 296).  Antibodies to additional PTPs may 
have a similar effect.  Perhaps a compound that stabilized or locked the dimerization state 
 121
would prevent activity.  It would be appealing to develop an inhibitor that would block the 
binding of a particular ligand and specifically affect downstream signaling.   
 
Conclusion 
The PTP field is experiencing an exciting time.  Long gone is the stigma that PTPs 
are just “housekeepers” cleaning up after PTK signaling.  PTPs are now considered to be as 
complex a group of proteins as PTKs, with activity regulated in specific ways.  With the 
classification of all PTP genes in mice and humans (2), we can ask more questions regarding 
the specificity, redundancy, tissue expression and isoforms/mutations of PTPs.  The 
development of the substrate trapping mutants has led to the identification of more substrates.  
Structural information regarding the extracellular and intracellular domains of PTPs is 
shedding new light on how catalytic activities are regulated.  Now the field needs to focus on 
the physiological roles or functions of individual PTPs.  One challenge facing researchers is 
that PTP expression and function may be regulated in a tissue-specific manner.  In which 
case, different substrates might be identified in different cell types, resulting in modification 
of current signaling pathway models.  Several PTPs have been linked to disease states such 
as diabetes, cancer and inflammation.  Knockout mouse models, siRNA, and the 
development of small molecule inhibitors will help to clarify the roles of PTPs in normal 
physiological processes and pathological conditions.  The future in PTP research possesses 
many discoveries for the years to come. 
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